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ABSTRACT

Author: Joshi, Rucha, Vinay. Ph.D.
Institution: Purdue University
Degree Received: December 2016
Title: Designer Collagen-Fibril Biograft Materials for Tunable Molecular Delivery
Major Professor: Sherry L. Voytik-Harbin
One of the biggest challenges in tissue engineering currently is the formation of a
functional microvascular network as part of an engineered tissue graft. Despite many
advances in tissue engineering methods, the field still awaits biograft designs that enable
neovascularization at clinically relevant size scales. Critical to the design of such
materials

are

tissue-specific

physico-mechanical properties

and controlled local

therapeutic molecular release.
The purpose of the current research is to develop such a multifunctional biograft
material from type I collagen polymers. Although collagen-based biomaterials have been
applied broadly to tissue engineering and local drug delivery applications, persistent
shortcomings

remain,

including

poor

mechanical

properties,

rapid

proteolytic

degradation, and cursory control over physical properties and molecular release profiles.
In large part, this is owing to 1) poor characterization of conventional formulations in
terms of their molecular composition and 2) inability to fully capitalize on the inherent
self-assembly or polymerization capacity of collagen.
Here we address current shortcomings through the development of self-assembling,
collagen-fibril biograft materials through integrated tissue engineering and molecular
delivery design. More specifically, collagen polymers specified by their intermolecular
crosslink composition and self-assembly capacity were used to customize and design
materials in terms of 1) collagen fibril microstructure and 2) proteolytic degradability,
collectively defining overall local molecular release profiles. Application of the designed
collagen biograft materials to control vascular endothelial growth factor (VEGF) release
for promoting neovascularization and tissue regeneration was shown using an established
in-vivo chicken egg chorioallantoic membrane (CAM) model.

xiv
Results indicated that the collagen polymers specified by their intermolecular
crosslink composition and self-assembly capacity can be used effectively to fashion a
broad range of multifunctional collagen-fibril biograft materials with tunable physical
and molecular delivery properties in absence of excessive processing and exogenous
crosslinking. Further, using heparin affinity-based VEGF retention in collagen constructs,
we demonstrated improved and accelerated neovascularization as well as cellularization
of the collagen biografts implanted on CAM. These highly porous collagen materials
comprise D-banded fibrils, resembling those found in tissues, and maintain their inherent
biological signaling properties, thereby providing an ideal platform for integrated tissue
engineering and molecular therapy design.
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CHAPTER 1.

INTRODUCTION

Soft tissue reconstruction is often required as a result of trauma, burns, tumor resection,
congenital defects, and chronic wounds.

Unfortunately, the lack or limited supply of

autograft tissues remains a major surgical challenge[1]. While various types of scaffolds
prepared from synthetic or natural materials have been used for simple reconstruction,
their effectiveness remains limited by slow neovascularization ultimately contributing to
poor functional integration, pain, and/or scarring. An ideal solution for clinicians would
be a designer biologic graft material that provides appropriate multi-scale structure and
function while fostering rapid vascularization for improved tissue integration and
regeneration.
Our long-term goal is to develop a multifunctional soft tissue graft material that provides
1) tissue-specific physico-mechanical properties and 2) controlled, local therapeutic
molecular release for accelerated neovascularization and functional tissue integration and
regeneration. Type I collagen, the predominant and major structural component of the
ECM represents an ideal natural polymer candidate for such integrated tissue engineering
and local molecular delivery strategies [2]. It possesses several advantages over other
materials, such as inherent self-assembly and biological signaling capacities, proteolytic
biodegradability, and low immunogenicity [3].
Despite the advantages of collagen as a natural biomaterial, its application as a
multifunctional delivery vehicle has been limited by the inability to precisely and
predictably

control

its

microstructure,

mechanical

properties,

and

proteolytic

degradability [4, 5]. Shortcomings associated with conventional collagen-based drug
delivery formulations include poor mechanical integrity, rapid proteolytic degradation,
and burst release of molecules. Exogenous processing and crosslinking, including
treatment with glutaraldehyde, polyepoxy compounds, or carbodiimides, are often used to
slow down degradation and prolong the release of molecules [6-8]. Unfortunately, such
strategies have been reported to have deleterious effects on the inherent biological
signaling capacity of collagen resulting in adverse tissue responses [4, 9-13]. Thus, in
order to harness the true potential of collagen as an ideal material for soft tissue repair
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and regeneration, there is an urgent need to remedy shortcomings in existing collagen
based formulations.
We plan to address this gap through development of designer polymerizable collagen
fibril matrices, capable of tunable therapeutic delivery, using self-assembling collagen
building blocks. The advantage of using self-assembling material is that it provides
ability to tailor specific bulk material properties, such as matrix stiffness, proteolytic
degradability, release profiles, at a molecular level. Recently, the Voytik-Harbin
laboratory has developed and characterized an uncommon set of collagen polymer
building blocks that demonstrate such a self-assembly, and can be used in the hierarchical
design and customization of collagen-fibril materials. These fundamental collagen
molecule building blocks predictably and reproducibly control the relevant fibril- and
matrix-level properties such as matrix pore size, permeability and diffusivity, stiffness,
and cell-instructive signaling [14, 15]. The unique feature of this technology is that it
capitalizes on the differential self-assembly or matrix-forming capacity of these collagen
polymer building blocks. Furthermore, no exogenous crosslinking is required to improve
mechanical integrity or slow proteolytic degradation. As such, resultant materials display
supramolecular fibril assemblies and biological signaling capacity inherent to in-vivo
extracellular matrices.
We now propose to extend this work by testing the central hypothesis that collagen
polymer building blocks specified by their intermolecular crosslink composition and selfassembly capacity can be used to modulate microstructure and proteolytic degradability
of collagen-fibril materials to create functional soft tissue grafts with tunable molecular
delivery, as illustrated in Figure 1.
The objective of the proposed work is to design and develop a self-assembling,
multifunctional collagen graft material that supports accelerated vascularization and
tissue integration and regeneration.
We decided to accomplish our objective by pursuing the following AIMS:
AIM 1: Design self-assembling collagen-based drug delivery system and define how its
specific molecular and fibril level features modulate molecular release.
AIM 2: Demonstrate application of self-assembled collagen graft materials towards
enhancing local neovascularization in an in-vivo chorioallantoic membrane model
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(CAM), through retention of heparin and vascular endothelial growth factor (VEGF)
molecules.

Figure 1: Schematics of design strategy for creating designer collagen biografts with
tunable molecular delivery.The strategy to achieve a multi-functional collagen biograft
from type I collagen is presented. It involves 1) modulation of collagen microstructure at
molecular and fibrillar level and 2) altering proteolytic degradability of matrix, as both
these parameters affect 1) solute/fluid transport and 2) cell fate and tissue formation.
1.1

Background

1.1.1 Motivation for applying collagen towards integrated tissue engineering and
molecular delivery
Chronic wounds, defined by the presence of a skin defect or lesion that persists longer
than 6 weeks or has a frequent recurrence [16], affect around 6.5 million patients in the
United States alone [17], and as many as 37 million globally [18]. Chronic wounds pose a
tremendous burden to the patients’ health as well as the economic system. An excess of
US$25 billion is spent annually on treatment of chronic wounds, and the burden is
escalating due to increasing health care costs, an aging population and a higher incidence
of diabetes and obesity [19].
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A common yet seriously challenging example of chronic wounds is a diabetic foot ulcer
(DFU) which due to its suboptimal healing properties, increases the risk of infection and
if not cured in timely manner, leads to leg amputation [20]. In 2010, about 73,000 nontraumatic lower-limb amputations were performed due to DFUs [21]. Costing $38,077
per amputation procedure, approximately 3 billion dollars are spent per year on diabetesrelated amputations [22].

An estimated 12% of individuals with a foot ulcer require foot

amputation , which is a serious concern considering the fact that the 5-year survival rate
after one major lower extremity amputation is about 50% [19].
Chronic wounds fail to heal because of the disruption of the orderly sequence of events
during the wound healing process. To understand pathophysiology of chronic wound, it is
necessary to know the physiology of normal wound healing process first. Wound healing
normally involves a complex interaction between epidermal and dermal cells, the
extracellular matrix (ECM), angiogenesis, and plasma derived proteins, all coordinated
through an array of cytokines and growth factors. This dynamic process can be classified
into four overlapping phases, including hemostasis, inflammation, proliferation, and
remodeling [23, 24], as depicted in Figure 2 and described briefly below.
i) Hemostasis: After tissue injury, thrombus formation requires an interaction between
endothelial cells, platelets, and coagulation factors to achieve hemostasis. Trapped
platelets within the clot trigger an inflammatory response through the release of
vasodilators, chemoattractants and activation of complement cascade.
ii) Inflammation: In the early phase of inflammation, neutrophils predominate and
remove bacteria and other foreign material from the wound by phagocytosis and release
of enzymes. Later in the inflammatory phase neutrophils reduce in number and are
replaced by macrophages. This stage lasts until about 48 h after injury.
iii) Proliferation: In this phase, fibroblasts play an important role in the synthesis of new
type I collagen and ECM. Additionally, tenascin, fibronectin, and proteoglycans are also
produced. Production of ECM is clinically seen as formation of granulation tissue. The
formation of new tissue combined with the contraction of surrounding tissues is essential
for the healing of wounds. While new matrix is synthesized, existing matrix in and
around the wound margin is degraded by several enzyme systems such as matrix
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metalloproteinases (MMPs) and plasminogen activators. This stage occurs about 2–10
days after injury.
iv) Remodeling: In this phase, type I collagen replaces fibronectin, becoming the
predominant ECM constituent and resulting in a more mature ECM. Once closure of the
wound has been achieved, remodeling of the resulting scar occurs over months or years,
with a reduction of cell content and blood flow in the scar tissue.

Figure 2: Fundamental interrelation of the wound healing phases : Hemostasis (red),
inflammation (blue), proliferation (green), and tissue remodeling (yellow). Figure
adopted from [23].
An important feature of the proliferation phase in normal wound healing is
neovascularization. The dynamic interactions between endothelial cells, various soluble
angiogenic cytokines, and the ECM environment promote neovascularization in the
wound as shown in Figure 3A [24]. Angiogenic capillaries sprout and invade the
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fibrin/fibronectin-rich wound clot and organize into a microvascular network throughout
the granulation tissue within a few days.

Figure 3: Normal versus impaired wound healing. Normal wound healing (A) versus
impaired wound healing (B). In a normal wound healing, fibroblasts construct new ECM
necessary to support cell ingrowth, and blood vessels that carry oxygen and nutrients
necessary for cell survival. The provisional ECM promotes granulation tissue formation.
Macrophages, fibroblasts, and blood vessels move into the wound space as a unit,
through dynamic biologic interactions contributing to tissue repair. Fibroblasts contribute
to new type I collagen synthesis. While MMP levels decrease through the normal woundhealing process, chronic wounds continue to show a significantly higher level of
proteases and pro-inflammatory cytokines. As a result, inflammation persists longer and
higher levels of MMPs cause excessive breakdown of type I collagen and ECM. Chronic
wound is healing is then further impaired by lack of neovascularization, and an impaired
re-epithelialization. Figure adapted from [29].
However, in chronic wounds, this dynamic spatio-temporal interaction between
endothelial cells, angiogenesis factors, and surrounding ECM proteins is impaired. The
chronic skin defect is usually in a permanent inflammatory state due to a hyper stimulated
neutrophil response[16].

Along with an elevated level of proinflammatory cytokines,

permanent increased proteolytic activity is typical for chronic wounds,

contributed by

excessive production of matrix metalloproteinases (MMPs) in the wound [25, 26]. MMPs
are said to be responsible for poor healing by breaking down too many components of the
ECM and by inhibiting growth factors that are essential for tissue synthesis [27]. This
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imbalance between ECM deposition and degradation, and deficiencies in growth factor
and cytokine receptors, lead to impaired progenitor cell recruitment and angiogenesis and
delay wound epithelialization [28].
Typically, wound debridement followed by its compression with sterile gauze is the
classic treatment for treating acute wounds [30, 31]. However, when this method is not
effective enough, chronic wounds have to be dressed with adequate biomaterials to
protect the long-term healing from infection and aiding in tissue regeneration [31, 32].
An intervention from alternative multifunctional tissue engineering strategy can therefore
offer a potential solution, by providing a strong structural template for cell infiltration and
growth of new tissue, and at the same time, providing local exposure of growth factors,
that can coordinate angiogenic response for full functional tissue recovery. The ultimate
goal for treating these wounds is scar-free healing and timely restoration of tissue
function [33].
1.1.2 Collagen based materials as wound dressings available commercially
As a major natural constituent of our body, collagen is seen to play an integral role in the
repair and replacement of soft tissue by providing an extracellular scaffold, stimulating
certain growth factors, and propagating tissue granulation [34]. As a result, numerous
efforts have been put into developing collagen implants and wound dressings to
specifically accelerate the natural process of wound healing and promote tissue
regeneration. Variety of products have been commercially developed and reviewed in
detail previously [34-40]. Selective examples of these products, including Oasis,
Alloderm, and Integra Dermal Regeneration Template products are described below. It is
claimed that the collagen in these products promotes the deposit of newly formed
collagen in the wound bed. These dressings come in variety of formats, including pads,
gels and particle forms. They can be used on surgical wounds, in deep wounds to fill dead
space, to absorb exudate and to provide a moist environment.
Alloderm (TM), distributed by the LifeCell Corporation, is a processed acellular dermal
matrix derived from human cadavers [41]. Cadaveric tissue samples are first screened for
a host of transmittable pathogens. The decellularization is achieved through use of
detergent solution, that leaves only the dermal matrix and associated basal lamina intact,
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removing all other cellular components [42]. Following decellularization, samples are
lyophilized for storage, and must be rehydrated before use [43]. Upon grafting, host
fibroblasts and associated vasculature infiltrates the Alloderm matrix. However, the full
extent of vascularization is said to be uncertain [44, 45]. The clinical use of Alloderm
also requires subsequent application of an ultrathin split-thickness autograft immediately
following implantation, since Alloderm lacks an epidermal component and has limited
barrier properties [44]. Other disadvantages of Alloderm are said to be requirement of
multiple applications and a theoretical risk of transmission of human pathogens [46].
Oasis(TM), developed by Cook Biotech, is an acellular dermal scaffold derived from
porcine small intestinal submucosa (SIS). It contains numerous dermal components
including collagen, glycosaminoglycans (hyaluronic acid), proteoglycans, fibronectin,
and bioactive growth factors such as fibroblast growth factor-2, transforming growth
factor β1, and vascular endothelial growth factor (VEGF) present naturally in the SIS
[47]. Following application to the wound bed, this acellular matrix is infiltrated by
fibroblasts and associated vasculature, which gradually replace the material with new
ECM components over time [48]. It should be noted that while the material has a limited
porosity, it does not provide a moisture barrier and must be protected by an appropriate
secondary dressing [49]. Oasis limitations therefore include possible higher infection rate,
and

need for multiple applications [46]. Clinical data with Oasis is also limited. A

clinical trial comparing the application of Oasis in 73 patients with diabetic foot ulcer
showed only slight statistical superiority (p=0.055) when compared with Regranex - a
carboxymethylcellulose-based topical gel containing recombinant human platelet-derived
growth factor (rhPDGF-BB) [50] .
Integra(TM) is a composite acellular collagen product developed by the Integra Life
Science Corporation. It is composed of an outer layer of silicone and a cross-linked
bovine type I collagen glycosaminoglycan dermal matrix and was originally described
by Yannas and Burke [51, 52]. The collagen-GAG matrix is gradually invaded by host
fibroblasts upon implantation in an excised wound bed [44]. Tissue integration is said to
take place in approximately 3-6 weeks, resulting in production of a 'neodermis' with
associated vasculature [44]. During this time the silicone layer acts as a protective barrier,
limiting moisture loss through the membrane [42]. Once the dermal layer regenerates,
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the silicone layer has to be removed and the wound is permanently closed with a split
thickness skin graft [34].
While Integra has shown promise in the treatment of chronic wounds and burns, it has a
number of limitations that hinder its clinical use. When compared with AlloDerm in a
mouse wound model, the Integra matrix induced more foreign body response and giant
cells, owing to the fact that it is a chemically cross-linked material [53]. Integra scaffold
needs to be first cleared by macrophages in order to allow deposition of collagen
fibers. Since Integra has no intrinsic immunological defenses, it can be easily infected by
bacteria and requires daily monitoring for signs of bacterial growth until the bio
integration process is complete [54]. In the incidence of infection, wound debridement
and reapplication are typically necessary, which further lengthens the time required for
healing [54]. Another concern is a two-step process required for Integra based therapy.
Since the silicone layer of Integra functions only as a temporary covering, it must be
replaced by an ultrathin autograft following neodermal formation [36]. Given that the
average acceptance rate of Integra is at least 10% lower than for a standard split-thickness
graft, patients might prefer to undergo the latter procedure directly instead of opting for a
riskier two-step process, if they have sufficient donor skin [36]. Furthermore, technical
difficulty in Integra application necessitates physician training, and as a result, it may
only be used by practitioners that have undergone a company sponsored training program
[55]. In an early trial, incidences of hematoma and seroma formation occurred due to
improper application of Integra, highlighting the level of skill required for proper use of
the material [52].
Thus, it is seen that despite the advantages of collagen based advanced wound dressings,
undesirable outcomes limit the use of these products in treatment of chronic wound
ulcers. In general, peripheral ischemia, which is a pathological characteristics of chronic
ulcers, critically affects collagen based biomaterial transplantations [56, 57]. Many
diabetic patients need surgical revascularization to achieve timely and durable healing.
However, with collagen-based wound therapies, it currently takes 3-4 weeks for
engineered dermal substitutes to be sufficiently vascularized, before a split-thickness skin
graft can be placed on the neodermis [58]. Thus, slow vascularization along with the
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inability of collagen based dressings to serve as stand-alone therapy adds to the
current limitations of collagen-based wound healing products, including frequent
surgical interventions, high costs of treatment, and inflammation mediated response
that leads to scar formation rather than tissue regeneration [34-39]. Thus, there is
acute need to improve vascularization period, and tissue regeneration capacity of
collagen-based products for clinical therapies.
1.1.3 Drug delivery from conventional collagen formulations: state of the art
To address the issue of slow vascularization and tissue regeneration through collagen
based products, alternative of combining growth factors into collagen [59-61] has gained
interest of researchers since many growth factors have been recently recognized as key
signaling molecules inducing wound healing [28]. For example, platelet-derived growth
factor-BB (PDGF-BB) is important for the granulation tissue formation and for stem cell
recruitment, vascular endothelial growth factor-A (VEGF-A) is needed to induce blood
vessel growth for sustaining the granulation tissue, and fibroblast growth factors (FGFs)
are crucial for both wound reepithelization and angiogenesis [62]. However, none of
these growth factor-loaded collagen matrices have reached commercial market as a
treatment available to patients. The reasons could be associated with the rapid clearance
from the matrix and/or degradation of soluble VEGF at the implant site [63, 64]. This
raises an important question on the ability of collagen to serve as a matrix to achieve
controlled release of growth factors.
Interestingly, to date, numerous studies report applications of collagen for controlled drug
delivery

as

ophthalmological

microspheres and

shields,

antibiotic-loaded

sponges,

drug

loaded

injectable collagen gels, and have been extensively reviewed

previously [4, 5, 65, 66]. Select representative examples of these formulations reported in
research articles are given in Appendix 1. Despite this wide research, close inspection
shows that only a few collagen-based drug delivery formulations have made it into
clinical trials or are currently marketed [4, 67, 68]. The selective examples of these
commercially available products are given in Table 1. It was observed that the majority
of these products are restricted to the delivery of an antimicrobial agent, silver (to prevent
infection in chronic wounds), and ethylenediaminetetracetic acid (EDTA) (to form a
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chelating complex with MMPs and to prevent them from excessively degrading matrix)
[69]. Thus, despite the numerous advantages and wide research on collagen as an
excellent natural biomaterial [4, 65, 67, 70, 71], its use as a vehicle for controlling local
growth factor release is seen to be limited [72, 73]. This points to yet another gap in
existing collagen based biomaterials - inability to achieve controlled release of
biomolecules.
Table 1: Examples of collagen based drug delivery products in market
(Source: Company based literature and BCC Market Research[74])
Drug
Delivery
System
Cogenzia

Company

Drug
Incorporated

Dressing format

Innocoll

Gentamicin

Lyophilized sponge

XaraColl

Innocoll

Bupivacaine
Hydrochloride

Vitagel™

Orthovita
Inc.

Thrombin

ColActive
® Plus Ag

Covalon

EDTA
and
silver ions

Promogran
Prisma™
Ag

Acelity

Silver-ORC
containing 25
%
w/w
ionically
bound silver
(Ag)

Biostep Ag

Smith & EDTA
and
Nephew
silver (Ag)

Application

Treatment of diabetic
foot infections
Local
Anesthetic
Sponge for
postoperative
pain
relief
Suspension
of Surgical
Hemostatic
bovine collagen and gel
bovine thrombin in
CaCl2 buffer
Lyophilized
Chronic
wound
collagen
sponge healing
made with collagen,
carboxyl
methyl
cellulose
(CMC)
and sodium alginate
Lyophilized sponge Healing chronic
consisting of 44% wounds such as
oxidized
diabetic
regenerated
venous and
cellulose
(ORC), pressure ulcers
55% collagen and
1% silver-ORC
Lyophilized sponge Healing chronic
made from porcine wounds such as
type I collagen and diabetic, venous, and
gelatin
pressure ulcers,
and burns
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The scarcity of collagen based drug delivery systems in market is concerning,
considering the wealth of information that exists on research-based collagen's drug
delivery systems. In deciphering why collagen based products might not be reaching their
full clinical potential, we reviewed the formulations of collagen used in current collagenbased biomaterials. As such, two main categories of formulations were identified, as
shown in Table 2. These are:
1. Non-dissociated Fibrillar Collagen- These formulations contain decellularized
collagen ECM particulate matter, which is mechanically homogenized, acidswollen, and finally lyophilized to form sponge which may or may not be crosslinked. Such collagen formulations do not undergo polymerization since collagen
fibers are never dissociated during this preparation method.
2. Soluble Collagen- These are obtained from pepsin or acid solubilization of
mammalian tissues to form viscous collagen solutions, which are then lyophilized
to form cross-linked or non-cross-linked sponge or injectable viscous gel. They
exhibit fluid like behavior under shear stress, and become entangled again when
the suspension is at rest.
Table 2: Major collagen formulations used in commercial drug delivery applications
of collagen-based biomaterials
Collagen
Formulation
Non dissociated,
Fibrillar Collagen

Solubilized
Collagen

Preparation
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The major limitation of these formulations is that they do not capture and capitalize the
inherent fibril self-assembly of collagen that occurs in vivo, and are limited by their poor
molecular characterization. As a result, the matrices formed from such formulations lack
interfibril branching and simply represent entanglements of long individual fibrils, that
lead to their poor shape definition, low mechanical integrity, poor handling, cell-induced
contraction, and rapid proteolytic degradation [4, 75-77]. To improve these properties,
materials are subjected to exogenous cross-linking, which is achieved through chemical,
enzymatic or physical methods [4].
Chemical cross-linking of type I collagen matrices is typically performed using
agents, such as glyoxal, formaldehyde, methylene diphenyl diisocyanate, hexamethylene
diisocyanate, and most commonly glutaraldehyde [4]. Glutaraldehyde and formaldehyde
treatment provides an advantage of cross-linking dry collagen material with reagent in
vapor phase instead of treatment in liquid phase [9]. Although these agents achieve the
goal of cross-linking, they also exhibit detrimental effects on cells and tissues [78] such
as cytotoxicity [6, 79] or tissue calcification [80-82]. For example, depolymerization of
polymeric glutaraldehyde cross-links has been reported to releases highly cytotoxic
glutaraldehyde and monomer fragments into the recipient [80, 83-85]. Cross-linking with
other

chemical

agents,

for

example,

diphenylphosphoryl

azide,

1-ethyl-3-(3-

dimethylaminopropyl) carbodiimide (EDC)/N-hydroxysuccinimide (NHS), and oxygen
species, were proved to be nontoxic, but the cross-linked fibers were unstable in water
and collapsed into films in aqueous or high humidity environments [86]. Besides, crosslinking can reduce porosity [82], limiting the nutrient transport to cells.
Researchers have also attempted to use physical cross-linking techniques such as
photooxidation, dehydrothermal treatments (DHT) and ultraviolet irradiation with
photosensitizers (e.g., riboflavin) to avoid introducing potentially cytotoxic chemical
residuals into the system and retain the biocompatibility of collagen materials [4].
However, most of these physical treatments cannot yield enough high cross-linking
degree to meet mechanical strength demand of drug delivery devices [77]. Furthermore,
collagen is reported to have been partially denatured by these physical treatments [8].
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Enzymatic cross-linking agents such as lysyl oxidase and tissue transglutaminase has also
been used however limited due to feasibility issues [87] and concerns of apoptosis [88]
respectively.
Thus, while materials formed without any cross-linking are characterized as
mechanically unstable, too soft to handle, and unable to resist cell-induced contractions,
exogenous crosslinking has been shown to have detrimental effects on cells and tissues
[78], such as cytotoxicity [6, 79] or tissue calcification [80-82] and partial denaturation of
collagen itself [86] [8].
1.1.4 Drug incorporation method in collagen delivery systems
While reviewing the application of collagen formulations in drug delivery
[4],[65],[5],[66], it was realized that the methods through which drugs are entrapped
within or attached to collagen delivery systems play an important role in determining the
efficacy of drug delivery system. Since drug release can be influenced drastically by the
approach taken to associate the drug with collagen matrix, it is important to understand
the current strategies of attaching drug to collagen. An informed decision made in
selection of strategy for drug attachment to collagen will endow us with a much better
tool to engineer drug delivery system with improved tunability, and cell-instructive
capacity.
Current strategies of drug incorporation can be separated into three distinct strategies
(Figure 6): i) physical entrapment of drug, ii) affinity binding based drug retention, and
iii) chemical or covalent immobilization of the drug into the collagen matrix.
Physical admixing involves direct entrapment of drug within matrix or encapsulation of
drug, and relies on diffusion to facilitate drug release into the surrounding tissue.
Chemical immobilization usually involves covalent binding through the use of chemical
crosslinkers and the drug is primarily released through degradation. Affinity binding
involves affinity based interaction between the drug and collagen substrate and drug
might be released by both diffusion and degradation.
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Figure 4: Schematics of strategies of drug incorporation in collagen based drug
delivery systems.
i) Physical admixing/entrapment/adsorption of drug into collagen: Physical admixing
involves dissolving or suspending the drug within a polymer reservoir to form a porous
device. It is the most common strategy used for local drug delivery due to its simplicity
and cost effectiveness [89]. Rate of drug release is controlled by diffusion dominated
mechanisms observed initially, followed by further release as reservoir degrades by
surface or bulk erosion [90].

Fabrication methods for entrapping drug involve

lyophilization (freeze drying), particulate leaching, phase emulsion (microspheres) and
in-situ polymerization (gels). Many of these methods start with slurries of shredded
collagen or whole collagen tissue fragments that are exogenously cross-linked, and
combined with drug at certain ratios before subjecting to lyophilization [91]. Sometimes,
the drug is added after lyophilization as in cases of collagen sponge. During
lyophilization, the pore-sizes that are formed within the matrices are often bigger than the
size of the drug, resulting in diffusion dominated release. However, there is little control
over pore size during lyophilization, which limits the ability to tune drug entrapment and
release. Moreover, harsh condition of processing in physical entrapment method (e.g.
homogenization used during emulsion method of formulating microspheres) can affect
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the bioactivity of encapsulated molecules by inactivating active sites or denaturing the
drug [92].
ii) Affinity based immobilization of drugs into collagen: Rather than simply admixing a
drug in collagen, site-specific tethering of drug to the collagen gives an option of
extending drug release by modifying the interaction between the drug and matrix.
Affinity can be described as the tendency for one molecule to bind to another. Affinity
based systems utilize the molecular interaction between the therapeutic agent and the
delivery vehicle. The strength of the interaction depends on the variety of molecular
forces: charge, hydrophobicity, hydrogen bonding, and van der Waals forces [93]. This
non-covalent physical adsorption technique involves adsorption of drugs onto surfaces
typically exploiting direct charge–charge or secondary drug-matrix affinity interactions,
or indirect interaction via intermediate proteins or other biological molecules (e.g.,
heparin [94], fibronectin [95]). Such interactions have been employed to deliver basic
fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) through
engineered biomimetic collagen matrices, showing controlled diffusion and matrix
degradation to induce angiogenesis [94, 96-99].
iii) Chemical / covalent immobilization of drug on collagen: Immobilization of the drug
within collagen matrix can also be achieved by its covalent conjugation to collagen.
Covalent binding of drugs to collagen matrices can sustain drug release for longer time
period and offer control over amount and spatial distribution of drug in collagen matrices.
Drugs can be conjugated to collagen matrices via functional groups, which are
incorporated by co-polymerization or through chemical treatment. For example, to
overcome rapid diffusion and clearance from the implant site and to increase its
conformational stability, recombinant transforming growth factor β2 (TGF-β2) was
covalently bound to injectable bovine dermal fibrillar collagen (FC), using a difunctional
polyethylene glycol (PEG) linker to create FC-PEG-TGF-β2 sequences throughout the
matrix [100]. The activity of the covalently bound TGF-β2 was compared to admixed
TGF-β2, and results showed that covalent binding of TGF-β2 to collagen resulted in a
significantly larger and longer-lasting TGF-β2 response than that observed with admixed
formulations of collagen and TGF-β2. It should be noted however, that despite
advantages offered by this method of drug incorporation, it is difficult to selectively

17
assign specificity of the coupling site on conjugated drug as binding interactions are
specific to each drug and difficult to predict. Also, biomolecules may lose their
bioactivity if screening or damage of the active pockets occurs during the immobilization
[61].
The ultimate success of any of the above method of drug loading, whether physical
entrapment, affinity based retention, or covalent immobilization, is dependent on the
preservation of collagen's native physiological properties. Physical entrapment and
affinity based molecular retention methods are often confounded by the weak mechanical
properties of conventional collagen formulations. As mentioned earlier, materials formed
without any cross-linking are characterized as mechanically unstable, too soft to handle,
and unable to resist cell-induced contractions [4, 75-77] thus failing to support cell
ingrowth and migration required for tissue regeneration. On the other hand, exogenous
crosslinking [4, 10, 12, 13, 86, 101, 102] or chemical immobilization based approaches
can lead to detrimental effects on cells and tissues [78], such as cytotoxicity [6, 79] or
tissue calcification [80-82] and partial denaturation of collagen itself [86] [8].
Consequently, current collagen based products suffer from problems related to
mechanical integrity, inability to give controlled release and inflammation based tissue
response. This limits the clinical success of collagen for tissue engineering and molecular
delivery applications [72],[103],[104].
1.1.5 An approach inspired by in-vivo collagen synthesis and self-assembly
It is realized that for promoting healing of chronic wound, there is a need for design and
development of a multifunctional collagen based platform that supports recreation of
natural type

I

collagen

fibril scaffold

while

fostering

rapid

and

functional

neovascularization and tissue regeneration at the site of implantation. Since the wound
healing period can vary according to wound type, age and many other factors including
infection, sex hormones, stress, diabetes, obesity, and medications [105], it is important
that such a multifunctional platform supports a broad range of customizable
spatiotemporal release profiles of biomolecules, through a loading strategy that does not
compromise physiologically relevant properties of native collagen. As such, we decided
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to take the inspiration from in-vivo collagen synthesis and self-assembly in the
development of such multifunctional tissue engineering and drug delivery platform.
In vivo, type I collagen constitutes a major structural and mechanical component of
connective tissues and organs, accounting for more than 90% of the ECM in skin, bone
and tendon of vertebrates [106] and approximately 30% of total body protein [2, 4]. Its
ability to form polymerizable, porous collagen-fibril matrix that can degrade into
physiologically non-toxic products make it an excellent biocompatible material with low
immunogenicity.

Additionally, its versatility and ability to be processed on an aqueous

basis make it a viable candidate for formulating drug delivery systems [107]. Being a
natural polymer, collagen also provides advantages related to its inherent cell-signaling
potential which is facilitated by adhesion domains that engage in integrin-mediated cell
binding [108]. These biophysical properties of collagen are summed up below in Figure
5.

Figure 5: Schematics showing biophysical properties of type I collagen that add to
its advantages for forming a tissue engineering and drug delivery platform.
The unique properties exhibited by type I collagen that are mentioned above are due to its
complex, unique hierarchical structure [109-113] developed during in vivo biosynthesis
and self-assembly. The basic building block of this hierarchical structure is a collagen
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molecule consisting of three peptide chains (two α1 (I) and one α2 (I) chain). Collagen
molecule comprises a central helical domain flanked on each end by non-helical
telopeptide domains [71, 114] as shown in Figure 6A. The 300 nm-long helical domain
consists of Gly-X-Y repeats where the X and Y positions are often occupied by proline
and hydroxyproline.

These collagen molecules, also known as tropocollagen, are the

fundamental building blocks of type I collagen. Tropocollagen molecules self-assemble
in a hierarchical fashion as shown in Figure 6B, to form tissue-specific networks of fibrils
that then combine to form suprafibrillar and tissue level structures [14].

Figure 6: A) Schematic of type I collagen molecular structure . Figure shows three
polypeptide chains intertwined to create a right-handed helical structure. The N- and Ctermini of the molecular structure contain the non-helical telopeptide regions. (From
[115]) B) Hierarchical, multi-scale organization of type I collagen as it occurs in vivo
(From[116]).
The in-vivo biosynthesis of collagen involves ribosomal production of individual
tropocollagen alpha (α) chains, followed by hydroxylation of specific proline and lysine
residues which contribute to triple helix stabilization and molecular cross-linking
respectively [14]. Processed polypeptide chains then undergo trimerization to form
heterotrimeric procollagen molecules consisting of two α1 (I) and a single α2 (I) chains.
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Upon extrusion into the extracellular space, both amino- and carboxy-terminal
propeptides are cleaved enzymatically [71], thus rendering the resultant tropocollagen
molecule capable of fibril formation [117]. As the prefibrillar aggregates of staggered
tropocollagen molecules assemble, lysyl oxidase binds and catalyzes cross-link formation
between prefibrillar aggregates of staggered collagen molecules (telocollagen) to create
covalently cross-linked dimers or trimers (called oligomers) [118].

These different

oligomer precursors direct the progressive molecular packing, fibril assembly, and
suprafibrillar network formation that eventually gives rise to tissue-specific form and
function [14, 119].
1.1.6 Proposed strategy to design collagen based drug delivery platform
Inspired by the in-vivo collagen synthesis and self-assembly, we wanted to create a
designer collagen biograft material that would provide a strong structural support, and
promote rapid neovascularization and tissue regeneration through tunable molecular
release.

We decided to achieve this goal through a combination of improved collagen

formulation, and by strategic use of physical or affinity based retention of molecules in
collagen. The unique type I collagen building blocks we employed in the design of such
multifunctional platform, were oligomers, and monomers such as telocollagens and
atelocollagens (Figure 7) that have been developed in Voytik-Harbin laboratory
previously. These unique collagen building blocks of oligomer, telocollagen and
atelocollagen are extracted from porcine skin type I collagen (PSC), and have been
previously proven to predictably and reproducibly control the relevant fibril- and matrixlevel properties such as matrix pore size, permeability and diffusivity, stiffness, and cell
surface-receptor mediated signaling [14, 120, 121].
These collagen building blocks differ in their intermolecular cross-link content,
composition and cross-link chemistries [14, 120]. While the oligomers comprise small
aggregates of collagen molecules (e.g., trimers), which retain collagen’s tissue-specific,
covalent intermolecular cross-links, telocollagens are individual collagen molecules,
which lack these intermolecular covalent cross-links. The telocollagen and oligomer
formulations possess intact telopeptide regions and contain reactive aldehydes building
blocks

generated from acid-labile, intermediate

cross-links

[14]. Upon in-vivo
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polymerization, the process through which collagen fibrils assemble to form a gelled
polymeric network, these reactive aldehydes spontaneously reform covalent, intermediate
cross-links as part of the fibril-forming process. Pepsin-solubilized (telopeptide-deficient)
atelocollagen formulations are created when collagen is treated with proteolytic enzymes
that remove the terminal telopeptide regions. As both the amino (N)- and carboxyl (C)telopeptides play important roles in cross-linking and fibril formation, their complete
removal results in an amorphous arrangement of collagen molecules and a consequent
loss of the banded-fibril pattern in the reconstituted product [122].

Figure 7: Collagen polymer building blocks as defined based on cross -link type. (A)
Oligomer, (B) Telocollagen (C) Atelocollagen. Stars and gray bars represent reactive
aldehydes and stable, mature covalent cross-links, respectively.
The matrices formed from these building blocks have previously shown superior
mechano-biological

properties

compared

to

commercially

available

collagen

formulations under the same polymerization conditions [120]. The microstructural and
mechanical properties given by these isolated unique building blocks are different from
that obtained from collagen formulations in other categories. The relationship between
matrix stiffness and fibril density, as exhibited by the building blocks was found to be
important in regulating the cell behavior and vessel morphogenesis [14]. PSC showed
decreased polymerization times, enhanced mechanical integrity and a larger dynamic
stiffness range than the other collagen formulations [14, 120]. It then became evident that
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fundamental differences existed between the porcine skin collagen and conventional
collagens on the molecular level, and these are most likely due to intermolecular crosslinking and ability of to self-assemble as demonstrated by porcine skin collagen building
blocks [14, 120, 123]. We decided to capitalize on these inherent strengths of collagen
building-blocks for controlling molecular release.
This work deals with application of these unique collagen building blocks towards
tunable molecular release through i) control of the fibril microstructure and proteolytic
degradability of collagen at molecular level, and ii) use of affinity binding based
approach that can prolong retention of molecules in collagen. Strategically, we employed
heparin that has binding affinity for oligomer as well as VEGF, for loading of the
VEGF189 molecules in oligomeric collagen, and tested its applicability towards
enhancing neovascularization in vivo using a well-established chicken egg chorioallantoic
membrane (CAM) assay.

1.2

Organization of thesis

This dissertation aims to demonstrate how specific molecular and fibril level design
features of collagen, along with affinity binding properties, can be used to tune the
molecular release from collagen biografts for applications such as improving local
vascularization and tissue regeneration in engineered collagen constructs.
In Chapter 2, we address our specific aim 1 of designing self-assembling collagen-based
drug delivery system of low and high fibril-density, and defining how its specific
molecular and fibril level features can modulate molecular release. We used FITCdextrans of various sizes ranging from 10kDa to 2000 kDa as a drug analogue in this aim.
After matrix self-assembly and polymerization, we compared the FITC-dextran release
from various collagen matrices in absence, and presence of collagenase. Weibull function
was fit to the empirical data to decipher associated release mechanisms. Through this
study, we first established use of oligomer as a robust drug delivery system compared to
commercial telocollagen-based drug delivery system. Next, we showed how molecular
release can be tuned by altering collagen molecular composition and fibril density.
Lastly, we showed how varying levels of collagenase could affect molecular release from
the low and high fibril density implants.
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In CHAPTER 3, we addressed specific aim 3 of demonstrating application of low and
high fibril-density collagen graft materials towards controlled VEGF delivery for
enhancing local neovascularization in an in-vivo chorioallantoic membrane model.

To

improve the local retention of VEGF in collagen, we exploited heparin binding affinity
towards collagen and VEGF189. The implants were evaluated for their ability to provide
enhanced neovascularization in an accelerated time frame of 3 days.
In CHAPTER 4, we summarize our findings while outlining the scope of future work.
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CHAPTER 2.
DESIGN AND MODULATION OF COLLAGEN
FIBRIL BIOGRAFTS FOR TUNABLE MOLECULAR RELEASE

2.1

Introduction

Type I collagen represents an important candidate biopolymer when considering the
design of multifunctional tissue implants. Being a natural biomaterial, it forms major
structural and mechanical component of the majority of connective tissues and organs in
our body. It accounts for more than 90% of the extracellular matrix (ECM) of vertebrates
[106] and approximately 30% of total body protein [2, 4]. Its hierarchical structure, selfassembly and intermolecular cross-links ubiquitously preserved across species [70], and
its ability to form porous collagen-fibril matrices with cell signaling potential make it an
excellent material for creating multifunctional drug delivery platforms for in-vivo
implantation.
The hierarchical organization of collagen during its in-vivo synthesis involves binding of
lysyl oxidase enzyme to catalyze cross-link formation between prefibrillar aggregates of
staggered collagen molecules (monomers) to create covalently cross-linked oligomers
(e.g., at least two collagen molecules joined by a covalent cross-link) [14, 124, 125].
These different oligomer precursors (dimers or trimers) in turn, direct the progressive
molecular packing and assembly of collagen that eventually gives rise to tissue-specific
fibril microstructure and matrix physical properties with exceptional cell signaling
potential, facilitated by adhesion domains that engage in integrin-mediated cell binding.
The porous microstructure and unique biochemical composition makes collagen a viable
candidate for drug delivery [4, 5, 65-67, 70, 71]

with most applications explored in

ophthalmologic [126-135] dental [136], [137], wound healing

[138-140] [141] [142,

143] [144] [145] [146], and bone regeneration [147-150] fields.
Despite this, only a handful of collagen drug delivery systems are commercially available
[5] [72, 151],[103],[104] [152].

Major shortcomings in conventionally available

collagens include poor molecular characterization; low mechanical integrity and stability;
rapid proteolytic degradation; limited design control; and deleterious tissue responses
associated with chemical modifications [4],[9],[10, 12, 13, 86, 101, 102].

Implants
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formed from conventional formulations are unable to form suprafibrillar structural
assemblies as observed in vivo, instead exhibiting amorphous microstructures [72, 73]
with low tearing strength [153],

poor mechanical integrity [154] [155], and an

uncontrolled molecular release [72] [156] [77] [156] [157] [158] [159]. Strategies to
overcome

these

limitations

include

utilizing

exogenous

cross-linking,

chemical

modification, or mixing with other natural/synthetic polymers (Appendix 2). However
these strategies have been associated with several limitations, including but not limited to
detrimental effects on cells and tissues [78], such as cytotoxicity [6, 79], tissue
calcification [80-82], and partial denaturation of collagen [86] [8] or biomolecule [160].
Here we address these shortcomings through the development of self-assembling,
collagen-fibril biograft materials that feature integrated tissue engineering and molecular
delivery design. More specifically, collagen polymers specified by their intermolecular
crosslink composition and self-assembly capacity [14, 120, 121] were used to customize
and design materials in terms of 1) collagen fibril microstructure and mechanical
properties and 2) proteolytic degradability. While these features were found to define
tissue formation and cell-instructive properties previously, here we exploited them to
define local molecular release profiles. The objective of the proposed work was to
develop a tunable, multifunctional, collagen-based platform that supports a broad range
of customizable spatiotemporal molecular release profiles, including burst and sustained.
The unique feature of this technology is that it capitalizes on the differential selfassembly of

collagen and avoids use of exogenous crosslinking or chemical

modifications.

2.2

Methods

2.2.1 Preparation of soluble collagen formulations
All laboratory-produced

self-assembling type

I

collagen formulations

(oligomer,

telocollagen, and atelocollagen) were derived from the dermis of market weight pigs.
Collagen oligomers were prepared as described previously [120]; telocollagen was
prepared by extracting porcine dermis with 0.5 M acetic acid followed by salt
precipitation [115, 121]; and atelocollagen was prepared via complete pepsin digestion
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[161]. All collagens were then dialyzed exhaustively against 0.1 M acetic acid and
lyophilized. Prior to use, lyophilized collagens were dissolved in 0.01 N hydrochloric
acid (HCl) and rendered aseptic by overnight exposure to chloroform at 4°C. Collagen
concentration was determined using a Sirius Red (Direct Red 80) assay [162].
Laboratory-produced collagens were standardized based upon purity as well as
polymerization capacity, as described in ASTM F3089-14[163]. Polymerization capacity,
as a functional performance criterion, is defined as the relationship between shear storage
modulus (G’) of polymerized matrices and collagen content of the polymerization
reaction [14, 120]. Commercial monomeric collagen, namely type I collagen acid
solubilized from rat tails, was purchased from Corning (Catalogue Number 354249;
Corning, NY, USA) and is referenced as rat tail collagen (RTC). All collagen solutions
were diluted with 0.01 N HCl to achieve desired concentrations and neutralized with 10X
phosphate buffered saline (PBS) and 0.1 N sodium hydroxide (NaOH) to achieve pH 7.4
[120]. Neutralized solutions were kept on ice prior to induction of polymerization by
warming to 37oC.
2.2.2 Polymerization kinetics and capacity of oligomer collagen in absence and
presence of FITC-dextran
Oligomer collagen polymerization kinetics and capacity were measured in absence and
presence of 10 kDa or 2000 kDa FITC-dextrans (Invitrogen, Eugene, OR) using an
AR2000 rheometer (TA Instruments, New Castle, DE,) equipped with a stainless-steel 40
mm-diameter parallel plate geometry [14, 120]. Oligomer solutions (3 mg/ml) were
prepared in the presence and absence of relatively high concentrations of FITC-dextran (1
mg/ml in 10X PBS), neutralized, and pipetted onto the Peltier plate. Upon lowering the
geometry, the Peltier plate was maintained at 4 0C for 5 minutes and then increased to
37°C for 15 minutes to induce collagen polymerization. Time-dependent changes in shear
storage modulus (G’) were measured at 1% controlled oscillatory strain. Each matrix
formulation was tested in triplicate (n=3).
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2.2.3 Collagen-fibril materials containing FITC-dextran
Collagen fibril matrices were self-assembled to entrap and deliver various sizes of FITCdextrans. We formulated matrices at both low fibril-density (3 mg/ml) and high fibrildensity (20 and 40 mg/ml) using the following procedures.
2.2.3.1 Low-density collagen-fibril matrices
Oligomer solutions (3 mg/ml) were polymerized in the presence and absence of 10 kDa,
40 kDa, or 2000 kDa FITC-dextran (0.5 mg/ml) as described above. For some
experiments, mixed oligomer: atelocollagen matrix formulations were prepared by
combining neutralized oligomer (3 mg/ml) and atelocollagen (3 mg/ml) solutions at
various ratios between 0:100 and 100:0. The neutralized collagen solutions with and
without FITC-dextran were kept on ice prior to the induction of polymerization. Collagen
solutions were then pipetted into 48-well tissue culture plates (Corning, NY) at 250 μL
per well. Due to the viscosity of the collagen solutions, positive displacement pipettes
(Microman, Gilson, Middleton, WI) were used. The collagen solutions were allowed to
polymerize for 30 min at 37°C in a humidified incubator.
2.2.3.2 High-density collagen-fibril matrices
High-density oligomer matrices were created using confined compression as described
previously [164]. Briefly, 10.4 ml and 20.8 ml neutralized collagen oligomer (4.05
mg/ml) containing 0.25 mg/ml of 10 kDa or 2000 kDa FITC-dextran were prepared,
pipetted into molds (2 cm width by 4 cm length), and polymerized overnight at 37°C.
Polymerized matrices were then densified using a porous polyethylene platen (50 µm
pore size) at 6 mm/min to final thickness of 0.26 cm, yielding matrices of 20 mg/ml and
40 mg/ml. Disks (1.1 cm diameter) were punched from the compressed materials and
placed in 48-well tissue culture plates for comparison with non-densified, 3 mg/ml
oligomeric collagen of identical dimensions. Each experimental group was prepared in
triplicate (n=3).
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2.2.4 Characterization of 3D collagen-fibril matrices
Both low and high fibril-density collagen fibril matrices were characterized in terms of
their microstructure and proteolytic degradability, as described below.
2.2.4.1 Micro-structural analysis
Collagen fibril microstructure was visualized via cryogenic scanning electron microscopy
(cryo-SEM) using an Everhart-Thronley detector adapted to a FEI NOVA nanoSEM 200
(FEI, Hillsboro, OR). Collagen materials were quick frozen by submersion into critical
point liquid nitrogen, transferred to a CT1000 cold stage attachment (Oxford Instruments
North America, Inc., Concord, MA), and sublimated under vacuum for 15 minutes before
platinum sputter coating and imaging. Each experimental group was prepared in duplicate
(n=2).
2.2.4.2 Sensitivity to proteolytic degradation
To test sensitivity of self-assembled collagen-fibril materials to collagenase degradation,
rheologic

testing

was

conducted.

Solutions

of

3 mg/ml neutralized oligomer,

telocollagen, or atelocollagen were polymerized on the rheometer plate in adherence to
the 40 mm-diameter parallel plate geometry for 30 minutes as described previously [14,
120]. Polymerized collagen materials were then exposed to 1.8 ml collagenase from
Clostridium Histolyticum (type IV, Worthington Biochemical Corporation, Lakewood,
NJ) reconstituted at 5000 U/ml, confined in a silicone ring. Time-dependent changes in
the tangent of phase shift delta (tan δ) were monitored in oscillatory shear using a time
sweep conducted at 1% controlled strain. Total degradation time was defined as time
required for inflection of tan δ to an absolute value great than or equal to 1, indicative of
matrix to liquid phase transition. Each material formulation was tested in triplicate (n=3).
2.2.5 Molecular Release from Collagen-fibril Matrices
2.2.5.1 Predicting sampling interval
Sampling time intervals for measuring molecular release kinetics from collagen materials
were determined using an established mathematical model for monolithic matrices [165].
This model, based on Fick's second law of diffusion, assumes a slab matrix geometry
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with homogeneous initial drug distribution and an associated supernatant “sink”. Shorttime equation (Eq. 1) was used for predicting first 60% of release, and long-time equation
(Eq. 2) was used to predict last 40% release [165].
Short-time equation:
1

Mt
Dt 2
= 4 ( 2)
M∞
πL

(1)

Mt
8
π2 Dt
= 1 − 2 exp (− 2 )
M∞
π
L

(2)

Long-time equation:

Here, Mt and M∞ denote cumulative amounts of molecules released at time t and at
infinite time respectively; D is the molecular diffusion coefficient within the system; and
L represents matrix thickness. Matrix thickness values were 0.26 cm as defined by our
experimental system. Diffusion coefficient values for 10 kDa, 40 kDa, and 2 MDa FITCdextrans were substituted as 1.09 E-10, 4.8 E-11, and 1.76 E-11 (m2/sec) respectively
based upon published experimentally determined values for 3 mg/ml oligomer collagen
matrices [121].
2.2.5.2 Measuring release kinetics
For measurement of release kinetics, polymerized collagen-fibril matrices were exposed
to 750 µl of either PBS (1X, pH 7.4) or collagenase from Clostridium Histolyticum (type
IV, Worthington Biochemical Corporation) prepared at desired enzyme strength in PBS
(1X, pH 7.4). At each sampling time, the supernatant was completely removed and
replaced with 750 µl of fresh buffer. Supernatant fluorescence was measured using a
spectrofluorometer (Molecular Devices Spectramax M5, Sunnyvale, CA) at excitation
and emission wavelengths of 493 and 530 nm, respectively. This process was repeated
until supernatant fluorescence for each well matched baseline fluorescence (PBS
plus/minus collagenase, no FITC-dextran), indicating complete FITC-dextran release. All
fluorescence values were normalized to maximum total fluorescence intensity and %
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cumulative release was plotted against time. Each formulation was tested in triplicate
(n=3).
2.2.5.3 Quantification of release kinetics and definition of molecular release
mechanism
FITC-dextran release from various collagen-fibril matrices was quantified using the
Weibull function [166] given in equation (3):
Mt
= 1 − exp (−at b )
(3)
M∞
Here, Mt is the molecular mass released at time t, M∞ is the molecular mass released at
infinite time (assumed equal to the amount of drug added), a denotes a scale parameter
that describes the time dependence, and b describes the shape of the dissolution curve
progression [167]. Here, to compensate for the sensitivity of Weibull function to minor
deviations when Mt/M∞ % is close to 0 and 100, a weighting procedure was employed
using (-log(1-Mt /M∞)*(1 - Mt /M∞ )2 as recommended by Jacobsen [168] and
Langenbucher [169]. Values of shape parameter b were used as an indicator of specific
molecular release mechanisms, as suggested by Papadopoulou and co-workers [170].
Time required to reach 50% of cumulative release (“T50 %”) was calculated from the
Weibull fit using Matlab (The MathWorks, Inc., Natick, MA).
2.2.6 Statistical analysis
The dependence of molecular release parameters as a function of FITC-dextran size and
matrix composition was determined using ANOVA followed by a post-hoc Tukey test
with a 95% confidence interval. A two-sample Student’s T-Test with a confidence
interval of 95% was used to compare molecular release parameters from matrices in the
presence and absence of collagenase. These statistical analyses were performed in
Minitab 16.0 (Minitab Inc., State College, PA). Interaction and contour graphs for
relationships between fibril density and collagenase level affecting T 50% of release, were
plotted in Minitab 16.0. The statistically-significant contribution of each factor,
specifically fibril density, collagenase level, and factor interaction, was determined using
two-way mixed model of ANOVA, through Proc MIXED procedure in Statistical
Analysis Software (SAS Institute, Cary, NC).
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2.3

Results

2.3.1 Admixed FITC-dextran did not affect oligomer self-assembly capacity
We and others have documented that collagen fibril self-assembly or fibrillogenesis is
dependent upon a number of polymerization parameters, including buffer composition,
pH and ionic strength, presence of copolymers (e.g., other collagen types) or accessory
molecules (e.g., proteoglycans), collagen molecule integrity (e.g., presence or absence of
telopeptides), as well as the presence of cells [14, 120, 162, 171-176]. Here, the effect of
FITC-dextran molecules on oligomer self-assembly, was determined by polymerizing
oligomer solutions (3 mg/ml) in the presence or absence of 10 kDa or 2000 kDa FITCdextran, each admixed at a relatively high concentration of 1 mg/ml. As shown in Table
3, values for polymerization half time (P 50%) and matrix shear storage modulus (G', Pa)
were statistically similar for oligomer prepared with and without FITC-dextran,
indicating no significant effect of these molecules on oligomer self-assembly capacity
(p=.592, n=3).
Table 3: Collagen polymerization properties

Composition

P50% (min)

Oligomer

0.62 ± 0.03

Oligomer + 10 kDa

0.57 ± 0.06

Oligomer + 2000 kDa

0.62 ± 0.04

A

A
A

G’ (Pa)
A

689.93 ± 52.46

A

641.69 ± 52.69

A

667.50 ± 60.13

2.3.2 Prediction of diffusion-based release from oligomer collagen suggested size dependent release of FITC-dextran molecules
Sampling intervals for drug release must be carefully timed to accurately capture and
depict material-based molecular release profiles. Sampling intervals for FITC-dextran
release from oligomer matrices were predicted using an established mathematical model
for monolithic materials [165] and experimentally determined FITC-dextran diffusion
coefficients[177]. As expected, the predicted time for diffusion-based release showed the
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tendency of larger molecules to be retained for longer times in oligomer matrices
compared to small molecules (Figure 8). Resultant time periods were also used to
determine supernatant collection time points for in-vitro molecular release studies.

Figure 8: Small-sized molecule release is predicted to be faster than that of large
sized molecules in 3 mg/ml collagen. Predicted size-dependent FITC-dextran release
profiles from 3 mg/ml oligomer matrices (A) and associated T 50% values (B) calculated
using diffusion-based models as described in the Methods section.
2.3.3 Comparison of ultrastructure and molecular release properties of collagen-fibril
matrices formed from lab produced oligomer solution vs. commercial RTC
solution
Matrices formed from conventional soluble collagen monomer formulations
(telocollagen and atelocollagen) have three notable shortcomings, namely high lot-to-lot
variability, poor structural integrity and high sensitivity to proteolytic degradation [164,
178]. As such, controlled molecular release using these materials has proven challenging
[157].

Oligomer collagen, with its uncommon molecular composition, has previously

been shown to possess low intra-hide and inter-hide variability [120], increased
intermolecular crosslinking [14, 121],

improved mechanical integrity [116], shape

retention, and resistance to cell-induced contraction compared to their monomer
counterparts [125, 177].
To compare the molecular release from oligomer and RTC matrices in both absence and
presence of collagenase, 3 mg/ml oligomer and RTC collagen solutions containing 0.5
mg/ml of 10, 40, and 2000 kDa FITC-dextrans were polymerized to form 3D matrices,
and then exposed to 1X PBS buffer with or without 125 U/ml collagenase.
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Visualization of self-assembled collagen-fibril ultrastructure with cryo-SEM (Figure 9A)
showed that oligomer fibrils were more uniform in size with a greater mean diameter
compared to RTC. These differences in microstructure and mechanical integrity between
oligomer and RTC matrices might have contributed to the differences in proteolytic
resistance of the two matrices, where RTC matrices showed dramatically reduced
resistance to proteolytic degradation resulting in rapid molecular release, compared to the
oligomer matrices.
2.3.3.1 In absence of collagenase, oligomer matrices but not RTC matrices display
size-dependent molecular release
When 3 mg/ml oligomer fibril-matrices containing various sizes of FITC-dextrans were
exposed to 1X PBS buffer without collagenase, distinct molecular size-dependent release
profiles were obtained as shown in Figure 9B. 10 kDa FITC-dextran was retained for the
shortest time with T50% of 11.40±1.25 hrs (mean±SD), followed by 40 kDa and 2000
KDa with values of 15.21±1.48 hrs, and 23.44±2.95 hrs respectively. While the release of
2000 kDa FITC-dextran was significantly slower than that of the smaller molecules
(p=.001, n=3), there was no significant difference in release kinetics for 10kDa and
40kDa. Release mechanisms, as determined using Weibull fits, were diffusion-based for
all molecules tested (Figure 9B). However, 10 kDa FITC-dextran was classified as
diffusion through a disordered substrate, while 40 kDa and 2000 kDa FITC-dextrans
represented diffusion through a normal Euclidian substrate. These results were
encouraging given that oligomer materials were prepared at relatively low collagen-fibril
densities, approximately 0.5% fibril dry weight [116].
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Figure 9: Matrices prepared with self-assembling collagen oligomers show different
fibril ultrastructures and molecular release profiles than commercial RTC matrices .
(A) Fibril ultrastructure of collagen-fibril matrices (3 mg/ml) prepared by polymerization
of oligomer or RTC, as visualized by cryo-SEM. Scale bar represents 4 μm. FITCdextrans (10 kDa (´), 40 kDa (□), or 2000 kDa (●)) were admixed within 3 mg/ml
oligomer and RTC solutions and, upon polymerization, time-dependent release from
matrices was monitored spectrofluorometrically in absence (B) and presence (C) of 125
U/ml collagenase. Black arrow in release profiles from RTC (C) marks complete
degradation of matrix. Tables indicate Weibull-fit based T50% (mean±SD), parameter
"b", and release mechanisms based on the value of “b”. Letters in T50% column indicate
statistically different experimental groups as determined by Tukey-Kramer range test
(n=3, p<0.05)
In contrast, conventional RTC matrices prepared at the same collagen concentration did
not show size-dependent molecular release (Figure 9B). T50% values ranged from
4.14±0.21 hrs for 2000 kDa molecules to 7.10±2.18 hrs for 10 kDa and were all
statistically similar. Moreover, the Weibull-based release mechanism, diffusion through
disordered substrate, was the same across the molecular size range tested. When
compared with oligomer, RTC matrices had significantly (p<0.05) lower T 50% values for
all FITC-dextran sizes.
Thus, the molecule size-dependent release profiles and associated distinctive release
mechanisms observed through mechanically and microstructurally integrated oligomer
matrices, but not RTC matrices, confirmed the viability of oligomer collagen-fibril
matrices as a drug delivery system with improved control over molecular release
compared to a conventional collagen-based drug delivery.
2.3.3.2 In presence of collagenase, oligomer matrices but not RTC matrices exhibit
sustained release
Typically, rapid proteolytic degradation-based release from conventional collagen
materials is prevented via exogenous crosslinking or chemical modification methods [4,
104, 159]. However, such methods have detrimental effects on cells and tissues [6, 7882], and on collagen itself [8, 86]. Here completely avoiding the need for exogenous
crosslinking or chemical modification, we attempted to control proteolytic degradation
based release using oligomer fibril matrices that possess enhanced interfibril associations
[179].
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Molecular release was measured in presence of 125 U/ml collagenase from both 3 mg/ml
oligomer and RTC matrices containing 0.5 mg/ml FITC-dextran (10, 40 and 2000 kDa).
Oligomer matrices exhibited significantly greater T50% for all FITC-dextrans, compared
to the RTC matrices (Figure 9C). Notably, oligomer matrices lasted for approximately 3
days at the high concentration of collagenase while RTC degraded in mere 4.8 hrs,
pointing to remarkable proteolytic resistance of oligomer matrices.
Weibull-fits indicated that the release mechanisms through oligomer changed from
diffusion through normal Euclidian substrate in absence of collagenase to diffusion
through disordered substrate in presence of collagenase. However, degradation based
release dominated RTC matrices, resulting in complex mechanism of release, where the
rate of release initially increases nonlinearly up to the inflection point and thereafter
decreases asymptotically [170]. This should be interpreted with caution though, since the
rapid degradation of RTC matrices dramatically reduced the sampling availability and the
quality of Weibull fits for RTC matrices, compared to the increased sampling and robust
Weibull fits observed with oligomer matrices.
Collectively, these results in presence of collagenase highlighted the ability of oligomer
matrices to resist proteolytic degradation and exhibit significantly sustained molecular
release, compared to the conventional RTC matrices.
2.3.4 Matrices composed from oligomer and atelocollagen exhibit significantly
different ultrastructure and release kinetics
Collagen polymer precursors oligomer, telocollagen, and atelocollagen differ in their
intermolecular crosslink composition and self-assembly capacity, giving rise to different
fibril densities [180] and matrix physico-mechanical properties [14, 15, 120]. Since these
parameters are known to affect mass transport[181], here we hypothesized that the
molecular release kinetics can be altered by changing the collagen compositional
precursors.
Ultrastructural differences between matrices prepared from oligomer, telocollagen, and
atelocollagen were visualized via cryo-SEM. While oligomer matrices displayed highly
branched, dense, and mechanically integrated fibrillar networks, atelocollagen matrices
were characterized with sparse, thin fibrils with minimal branching (Figure 10A).
Telocollagen matrices showed an intermediate fibril branching and entangled fibrils.
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Influence of different precursors (3 mg/ml oligomer, telocollagen, and atelocollagen) on
release of

10 kDa and 2000 kDa FITC-dextran (0.5 mg/ml) was observed in both

absence (Figure 10 B) and presence of 125 U/ml collagenase (Figure 10 C). Release
profiles for atelocollagen differed significantly from oligomer and telocollagen (p<.001;
n=3) For instance, the T50% exhibited by atelocollagen matrices for 10 kDa was
0.49±0.09 hrs, significantly lower (p<0.001, n=3) than that for oligomer (11.40±1.25 hrs)
and

telocollagen

(10.50±1.22

hrs)

matrices.

Similarly,

atelocollagen

exhibited

significantly lower T50% in case of 2000 kDa FITC-dextran compared to oligomer and
telocollagen matrices. Oligomer and telocollagen values were however not significantly
different. Furthermore, Weibull fitting indicated that the release mechanisms were
different through atelocollagen matrices when compared to telocollagen and oligomer
matrices, in both absence (Figure 10 B) and presence (Figure 10 C) of collagenase. The
molecular release was accelerated from all matrices in presence of collagenase,
elucidating role of proteolytic degradation in release.

38

39
Figure 10: Molecular release profiles of self-assembled collagen-fibril matrices are
dependent upon collagen polymer composition. (A) Fibril ultrastructure of collagenfibril matrices (3 mg/ml) prepared by polymerization of atelocollagen, telocollagen, and
oligomer as visualized using cryo-SEM. Scale bar represents 4 μm. FITC-dextrans (10
kDa or 2000 kDa) were admixed within 3 mg/ml atelocollagen (), telocollagen (□), and
oligomer (●) solutions, and upon polymerization, time-dependent release was monitored
spectrofluorometrically in absence (B) and presence (C) of 125 U/ml collagenase.
Associated tables indicate Weibull-fit based T50% (mean±SD), parameter "b", and release
mechanisms interpreted based on the value of “b”. Letters in T 50% column indicate
statistically different experimental groups as determined by Tukey-Kramer range test
(n=3, p<0.05).

The proteolytic degradation was observed to be different for matrices formed form
different precursors, as

determined by exposing each of the matrices to 5000 U/ml

collagenase on rheometer. Time sweep tracking transition of matrix from solid to liquid
phase then indicated that the degradation time for each type of matrix was significantly
different (p<0.001; n=3), as shown in Table 4. Atelocollagen matrices degraded fastest,
followed by telocollagen and then oligomer matrices.
Collectively, these results highlighted the slowest and fastest release kinetics displayed
by oligomer and atelocollagen precursor based matrices, identifying them as viable
candidates for further tuning of molecular release from collagen.
Table 4: Matrix degradation time

Matrix

Time (min)

Oligomer

219.5 ± 10.9

Telocollagen

186.7 ± 19.7

Atelocollagen

138.0 ± 1.0

A

B

C
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2.3.5 Tuning molecular release from collagen-fibril matrices
The structure, density, and integrity of fibrillar and nonfibrillar ECM components are
major factors in regulation of interstitial transportation and mediation of cellular
responses during physiological and pathological states in human body [182]. Here we
wanted to capture these features to modulate molecular release from collagen-based
materials. As such, we chose to systematically alter collagen fibril microstructure and
proteolytic degradation through 1) change in compositional ratio of oligomer and
atelocollagen precursors in the matrix, and 2) change in the polymerized oligomer fibrilmatrix density. While first strategy enabled tuning release through changes to collagen
made before polymerization, second strategy enabled to do so after polymerization of
collagen.
2.3.5.1 Oligomer and atelocollagen mixed matrices enable tuning polymerization
kinetics, ultrastructure, and molecular release kinetics
Whittington et al. [121, 180] previously showed that by varying oligomer to telocollagen
ratio, matrix mechanical properties as well as cell growth and differentiation can be
guided. Park et al. further elucidated effect of modulating collagen precursor ratios on
mass transport properties of collagen through computational modeling[181]. Here, we
aimed at determining the effect of modulating collagen precursors, specifically 3 mg/ml
oligomer and atelocollagen, on molecular release kinetics of both small and large sized
FITC-dextran. Therefore, neutralized oligomer and atelocollagen solutions (3 mg/ml)
were mixed in ratios 0:100, 25:75, 50:50, 75:25, and 100:0 respectively and its effects
were assessed on the collagen polymerization kinetics, viscoelasticity, and molecular
release kinetics.
Mixing resulted in matrices with significantly different polymerization kinetics and
stiffness (p<.05, n=3; Figure 11). Matrix stiffness and polymerization rate correlated
positively with increase in oligomer content. All matrices except 100% atelocollagen
polymerized within 5 minutes. Cryo-SEM was performed to determine the effect of
mixing oligomer and atelocollagen precursors on collagen fibril ultrastructure (Figure
12A). The 100% oligomer matrices demonstrate increased fibril thickness, density, and
interconnectivity when compared to 100% atelocollagen matrices. Matrices containing
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equal proportions of oligomer and atelocollagen showed intermediate fibril density and
interconnectivity.

Figure 11: Collagen polymerization kinetics are dependent upon the oligomer:
atelocollagen ratio. Time-dependent changes in shear-storage modulus were monitored
as collagen formulations transitioned from solution to matrix following an increase in
temperature from 4⁰C to 37⁰C. (A) Time-dependent changes in shear storage modulation
during polymerization were used to quantify (B) polymerization rate (mean±SD) and (C)
polymerization half-times (P50%; mean±SD). Each sample was tested in triplicate
To determine the effect of mixed matrices on molecular release kinetics,
neutralized collagen solutions (3 mg/ml) containing either 10 kDa or 2000 kDa FITCdextran were prepared from oligomer and atelocollagen, then mixed in ratios of 0:100,
5:95, 10:90, 50:50, 75:25, and 100:0 respectively. Upon polymerization, matrices were
exposed to 1X PBS buffer with no collagenase or 10 U/ml collagenase.
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Figure 12: Collagen-fibril matrix molecular release can be tuned by varying the
oligomer:atelocollagen ratio. (A) Fibril ultrastructure of collagen matrices (3 mg/ml)
prepared by polymerization of oligomer and atelocollagen mixed at different ratios as
visualized by cryo-SEM. Scale bar represents 4 μm. FITC-dextrans (10 kDa and 2000
kDa) were admixed within oligomer:atelocollagen solutions prepared at 0:100 (ο), 5:95
(), 10:90 (□), 50:50(●), 75:25(◊), and 100:0 () ratios and, upon polymerization, timedependent release of FITC-dextrans was monitored spectrofluorometrically in the
absence (B) and presence (C) of 10 U/ml collagenase.
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In the absence of collagenase (Figure 12B), mixed matrices exhibited different release
profiles, for both 10 kDa and 2000 kDa FITC-dextrans. Release was prolonged with
increase in oligomer proportion in the mixed matrices. 2000 kDa FITC-dextran was
retained for a longer time than 10 kDa FITC-dextran, indicating molecular size dependent
release characteristic of mixed matrices. Further, the presence of collagenase highlighted
the distinction between release profiles of various mixed matrices (Figure 12C), with a
more pronounced effect on 2000 kDa FITC-dextran. The exaggerated differences in
release profiles observed in the presence of collagenase might be attributed to the
differences in proteolytic degradability associated with each collagen matrix component
seen earlier (Table 4).
Collectively, this method of changing collagen matrix composition through varying
oligomer and atelocollagen ratio shed light on its effectiveness on tuning molecular
release of both small and large sized molecules, through modulation of microstructure
and proteolytic degradation.
2.3.5.2 Oligomer densification tunes matrix ultrastructure and molecular release
Previously, using the method of confined compression, Blum et al. prepared high fibril
density oligomer matrices that possessed higher-order interfibril associations, and
mechanical properties of soft connective tissues [116]. Due to the smaller matrix pore
sizes [183] and increased resistance to proteolytic degradation [116] associated with these
high fibril-density collagen matrices, we hypothesized that confined compression can be
used to extend drug release from collagen fibril matrices.

To test this hypothesis,

polymerized 4.05 mg/ml oligomer matrices containing 0.25 mg/ml FITC-dextran (10 kDa
or 2000 kDa) were subjected confined compression [164], yielding 20 and 40 mg/ml
densified matrices.
The effect of densification on matrix ultrastructure was revealed by cryo-SEM (Figure
13A).

Densified matrices exhibited enhanced fibril density and higher-order interfibril

associations, in agreement with Blum et al. [164].
The effect of densification on molecular release from collagen-fibril matrices was
determined by exposing matrices to 1X PBS buffer containing either no collagenase
(Figure 13B) or 10 U/ml collagenase (Figure 13C). Significantly prolonged the release
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was observed from 20 and 40 mg/ml matrices, compared to 3 mg/ml matrices (p<0.001,
n=6). For 10 kDa FITC-dextran release, while the 40 mg/ml matrices gave a T50% value
of 14.02±2.16 hrs, 20 mg/ml matrices closely followed with a value of 13.61±1.10 hrs.
However, low fibril-density (3 mg/ml) matrices exhibited lowest value of 1.7±0.41 hrs.
This distinction between molecular release properties of high fibril-density and low fibrildensity matrices was maintained for 2000 kDa FITC-dextran release as well, since the
T50% of 20 and 40 mg/ml matrices (229.42±10.22 hrs and 339.85±3.56 hrs) were
significantly longer than that for 3 mg/ml matrices (36.18±4.84 hrs). These higher values
of T50% exhibited by high fibril density matrices were most striking, especially in the
absence of any exogenous modification of collagen. Thus, 20 mg/ml and 40 mg/ml
matrices provided a remarkable extension of 2000 kDa FITC-dextran release for up to 44
and
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days

respectively,

which

is

well

above

the

release

period

of

uncrosslinked/unmodified conventional collagens [4, 5, 66]. Exposure of low and high
fibril density matrices to 10 U/ml collagenase further elucidated the role of proteolytic
degradation in molecular release. Degradation accelerated release of 10 kDa (Figure 13C)
as well as 2000 kDa (Figure 13D) FITC-dextran. It also amplified the distinctness of
release profiles given by low and high fibril-density matrices. While 3 mg/ml matrices
showed rapid release of 10 kDa FITC-dextran (T50% 1.03±0.49 hrs), 20 and 40 mg/ml
matrices showed significantly extended (p<.001, n=6) release (T50% 8.72±1.94 hrs and
11.98±1.70 hrs respectively). This distinctness of molecular release between low and
high fibril density matrices was maintained in case of 2000 kDa FITC-dextran, with 3
mg/ml matrices showing lowest T50% (4.64±1.20 hrs), followed by 20 mg/ml
(39.68±7.55 hrs) and 40 mg/ml (69.20±10.15 hrs) matrices. These results point to
enhanced collagenase resistance of high fibril density matrices that must have contributed
to the longer retention of molecules compared to that by the low fibril density matrices.
Weibull fits showed diffusion-based release mechanisms for both 10 and 2000 kDa
FITC-dextrans in absence of collagenase, but complex release mechanisms in presence of
collagenase. Additionally, increased value of parameter "b" obtained for high fibrildensity (20 and 40 mg/ml) matrices reflected the decrease in disorder of the system at
high fibril density compared to low fibril-density [170].
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For 10 kDa, Weibull fits indicated both diffusion- and proteolytic degradation-based
molecular release mechanisms for 20 and 40 mg/ml matrices. The 3 mg/ml matrices
exhibited diffusion through disordered substrate, as expected from previous results. For
2000 kDa, 20 and 40 mg/ml matrices showed complex release mechanisms while 3
mg/ml matrices exhibited diffusion through a disordered substrate. Release mechanisms
differed with collagen-fibril density in the presence of collagenase.
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Figure 13: Increasing fibril density of oligomer matrices prolongs molecular release.
A) Fibril ultrastructure of 3 mg/ml, 20 mg/ml and 40 mg/ml oligomer matrices as
visualized using cryo-SEM. Scale bar represents 4 μm. Time-dependent release profiles
of 10 kDa and 2000 kDa FITC-dextran from 3 mg/ml (), 20 mg/ml (□), and 40 mg/ml
(●) oligomer matrices were monitored spectrofluorometrically in the absence (B) and
presence (C) of 10 U/ml collagenase. Associated tables indicate Weibull-fit based T50%
(mean±SD), parameter "b", and the release mechanisms interpreted based on the value of
“b”. Letters in T50% column indicate statistically different experimental groups as
determined by Tukey-Kramer range test (N=3, p<0.05)
2.3.6 Oligomer fibril density modulates molecular release at various collagenase
levels
Tunablity in proteolytic degradation based molecular release is highly desirable in
applications such as wound healing, where different levels of collagenase exist [184]. In
wounds with high protease level, normal wound repair process is obstructed, and together
with altered cytokine expressions, matrix repair and degradation rate is affected [23, 185,
186]. In such situations, densified oligomer-fibril matrices could accelerate wound
healing, due to their high mechanical strength, resistance to proteolytic degradation, high
cell signaling capacity [116], and ability to provide sustained molecular release. On the
other hand, faster molecular release from low fibril-density matrices may be beneficial in
acute wounds where protease levels are low and wounds heal faster. However, even in
each type of wound, collagenase levels are affected by the pathophysiological states, invivo locations, as well as by the age of the wound [187-189]. Therefore, it is important to
characterize the tunability in molecular release of collagen fibril matrices under varying
collagenase levels [190] [191].
To capture this scenario of varying collagenase concentrations, molecular release from
different fibril density matrices (3 mg/ml, 20 mg/ml and 40 mg/ml) was determined in the
absence (0 U/ml), or presence of low (10 U/ml) and high (100 U/ml) collagenase levels.
These levels were chosen as representatives of collagenase in physiologically normal
state, acute wound and chronic wound conditions respectively

[184, 187, 192]. This

study was focused on molecular release of small sized FITC-dextran (10 kDa) only, since
large molecular release is easier to control [4, 5, 193].
Results show that an increase in fibril density of oligomer matrices affects the
T50% values positively, while the increase in collagenase level affects these values
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negatively (Figure 14A). An interaction exists between fibril density and collagenase
levels (Figure 14B). Mixed ANOVA further confirmed that both the collagenase level,
fibril density, and their interaction affected T50% significantly (p<0.001, n=6). The
molecular release from 40 mg/ml matrices was most sustained, followed by 20 mg/ml
and 3 mg/ml matrices at all collagenase levels (Figure 15). Contour graph of T50% plotted
as a function of collagenase level and fibril density (Figure 14) further elucidated that
matrix fibril density played a greater role in tuning the T50% than the collagenase level.
These results highlight the ability of oligomer fibril matrices to modulate
molecular release in presence of varying levels of collagenase, based on the alteration of
their fibril density. This is a significant achievement for high fibril-density oligomer
matrices, considering the absence of any exogenous crosslinkers or chemical modifiers
that are typically applied to control molecular release from conventional collagen
matrices.
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Figure 14: Oligomer matrix molecular release is dependent upon fibril density and
collagenase level. 10 kDa FITC-dextran was admixed within 3 mg/ml, 20 mg/ml, and 40
mg/ml oligomer matrices and release kinetics were monitored spectrofluorometrically in
the presence of 100 U/ml, 10 U/ml, and 0 U/ml collagenase. A) Table indicates Weibullfit based T50% (mean±SD), parameter "b", and related release mechanisms. Letters in
T50% column indicate statistically different experimental groups as determined by TukeyKramer range test (n=3, p<0.05). B) Interaction plot for different fibril density oligomers
at various levels of collagenase. C) Corresponding contour plot showing the influence of
various levels of oligomer fibril density and collagenase on T 50% of release for 10 kDa
FITC-dextran.
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Figure 15: Oligomer matrix molecular release is dependent upon collagenase level.
Time-dependent release profiles for 10 kDa FITC-dextran admixed within 3 mg/ml, 20
mg/ml, and 40 mg/ml oligomer matrices were monitored spectrofluorometrically in the
presence of 100 U/ml (), 10 U/ml (□), and 0 U/ml (●) collagenase.
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2.4

Discussion

Many complex biological tissues in the human body, including collagen-based tissues,
display some remarkable features in common, including molecular self-assembly,
hierarchical organization at the atomistic, molecular, and macro scales, as well as
multifunctionality [194]. It is the microstructure and proteolytic degradability of the
formed tissue that then plays an important role in regulating the mass transport through
body. Therefore to control molecular transport through collagen based matrices in vitro, it
is important to mimic collagen self-assembly, and provide control over the microstructure
and proteolytic degradability of resultant matrices.

However, the conventional

monomeric collagen (telocollagenic and atelocollagenic) formulations fail to capture the
self-assembly

characteristic

of

collagen.

Unlike

oligomers,

these

conventional

monomeric formulations do not retain their tissue-specific, covalent intermolecular crosslinks [125]. As a result, the matrices formed from conventional collagen formulations
display weaker mechanical integrity and rapid proteolytic degradation. Consequently,
they fail to retain molecules/drugs for longer time and cannot be tuned to match their
release rates to desired need.
To address this gap, we decided to employ a collagen polymer engineering
approach that is inspired by the in-vivo collagen-fibril assembly. By incorporating
collagen natural intermolecular cross-link chemistries through oligomer building blocks
[14] we created self-assembled collagen fibril matrices that retained their multiscale
structure and biological signaling properties. This work explores the viability of these
self-assembled collagen fibril matrices in serving as multi-functional platforms for
delivery of a wide range of sizes of molecules. Through systematic variation of collagen
polymer composition and fibril density, we demonstrated the capability of these matrices
to tune molecular release based on modulation of microstructure and proteolytic
degradability features of matrix as the two main regulators of molecular transport.
Notably, this tunability in molecular release under both proteolytic and non-proteolytic
conditions, is

achieved without using any exogenous crosslinking or chemical

modification.
In order to design and validate the potential of oligomers to formulate a multi-functional
drug delivery system, we admixed oligomeric collagen with FITC-dextrans of sizes 10
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kDa, 40 kDa and 2000 kDa and polymerized them to form 3D collagen-fibril matrices of
3mg/ml density. FITC-dextrans molecule sizes were chosen to span a range of
therapeutic molecules including growth factors, antibodies, antibacterial agents, viruses,
nanoparticles, and plasmids[195].
An important aspect of our experimental procedure was to emulate the in-vivo molecular
release kinetics. Literature indicates that molecular release in vivo occurs by a
combination of diffusion and enzymatic breakdown of the collagen matrix [196]. In
pathological diseases such as cancer [197, 198] and chronic foot ulcers [188] well as
during normal tissue homeostasis, [199], proteolytic degradation of collagen is caused by
members of matrix metalloproteinase (MMP) family. To capture these in-vivo behaviors,
we measured the release kinetics of FITC-dextran infused oligomeric matrices under two
scenarios: 1) in absence of collagenase (diffusion only); or 2) in presence of collagenase
(diffusion+degradation). The in-vitro model system we adopted for measuring release is a
well-established model that has been used in the past by several researchers for
quantifying molecular release from various collagen-based drug delivery systems[137,
200-206]. In this model, the drug-containing collagen matrices are typically submerged in
a small volume of PBS buffer (typically 400 to 2500 μL) with or without collagenase, the
system is subjected to gentle shaking and the buffer volume is replaced periodically in the
given release study period, to quantify drug elution at various time points. In our system,
we chose 750 μL buffer volume for submerging collagen matrices as this volume was
within the range of previously reported buffer volumes [137, 200-206] and could fit in a
48 well tissue-culture plate. We then

subjected the entire plate to gentle shaking

conditions and periodically replaced buffer with fresh volume, that allowed us to quantify
release kinetics based off of fluorescence of FITC-dextrans eluted at a given time point.
Along with quantifying molecular release kinetics, the understanding of release
mechanisms involved in the release process is crucial when designing a controlled release
system[207]. For understanding and elucidating the mechanisms of drug release,
empirical modeling of drug release has been found to play an important role [208-210].
Characterizing molecular release from polymer matrices have been accomplished through
use of various empirical models, including the well-known Higuchi, and Peppas and
Weibull models [211-218].

The basic mathematical expressions used to describe the
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release kinetics and discern the release mechanisms are elegantly described in the articles
on Higuchi law [219] and the Peppas equation or the so-called power law ([220-222]).
Despite their wide use, [170, 216-218, 223], both Higuchi and power law are short time
approximations of complex exact relationships[223, 224], therefore, their use is confined
to the description of the first 60% of the release curve[170]. Beyond 60%, the quality of
the fit has been observed to be poor. However, Weibull function has been found to be
appropriate for fitting the entire set of data while effectively explaining the mechanisms
of molecular release [170, 225-228]

and has been applied successfully by several

researchers for discernment of drug release mechanisms [166, 226-237]. Therefore, in
this study, Weibull function was used to fit release data, quantify T 50%, and decipher the
associated release mechanisms.
2.4.1 Oligomeric collagen enables formation of multi-functional platforms with
robust microstructure and extended molecular release characteristics
To avoid the use of external agents, and yet maintain the mechanical integrity of collagen
based drug delivery system, we used novel self-assembling oligomeric collagen building
blocks that show a unique ability to form hierarchical fibrillar structures similar to those
found in vivo [115, 177]. These building blocks also possess many critical design features
amenable for engineering 3D cellular microenvironments, such as ability provide
mechanical support as well as biological cues for cell proliferation

[14, 120, 177, 179,

238]. A number of factors such as microstructure, matrix composition, and extent
exogenous cross-linking can affect mass transport through collagen-based tissues and
matrices [239-241]. Whittington et al. [177] recently showed that the inclusion of
intermolecular cross-links as a component of the fundamental collagen building blocks
(oligomers) affects molecular diffusion within polymerized matrices by regulating
hierarchical assembly and interfibril branch formation. Here we extend upon that work by
showing that oligomer collagen matrices affect the molecular release of FITC-dextrans
differently than conventional telocollagenic (RTC) matrices, both in the absence and
presence of collagenase. In absence of collagenase, large FITC-dextran (2000 kDa)
release was significantly extended (p<0.05, n=3) when compared to small FITC-dextrans
(10 kDa and 40 kDa) through oligomeric, but not RTC matrices.

Release profiles

through oligomer matrices were distinct for both smaller and larger molecules, as
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expected from predictive models of diffusion-based release (Figure 8). On the other hand,
RTC matrices showed lumped release profiles (not distinguished based on sizes of FITCdextrans). These results demonstrate the ability of oligomeric matrices to exhibit
molecular size-dependent release, similar to what is observed in in-vivo tissues such as
sclera [242] or brain ECM [243]. This is impressive because conventional collagen
matrices have not been able to achieve such a size dependent release without exogenous
crosslinking or modification with additives [78, 244, 245]. It is now known that crosslinking agents such as glutaraldehyde can exhibit detrimental effects on cells and tissues
[78] and non-collagenous additives affect the physiological properties of matrices.
In simultaneous experiments with collagenase (125 U/ml), ability of oligomer fibril
matrices to give sustained release (Figure 9C) was highlighted, in contrast to the rapid
release displayed by RTC matrices that were completely degraded in just 4.8 hrs.
However, at the same high collagenase level, the oligomer matrices persisted for about 3
days, highlighting their enhanced resistance to proteolytic degradation.

Notably, this

resistance is observed in absence of any exogenous crosslinking, while it is typical to use
exogenous crosslinkers in conventional collagen formulations for obtaining sustained
molecular release in presence of collagenase[192, 246, 247].
The molecular release differences observed between oligomer and RTC matrices could
be attributed to their ultrastructure differences (Figure 9A). Cryo-SEM comparison of 3
mg/ml oligomer matrices with conventional telocollagenic RTC matrices revealed that
oligomer matrices had a uniform, interconnected porous nature when compared to the
non-uniform fibril ultrastructure and weak mechanical stability of conventional RTC
matrices. Oligomer matrices also exhibited superior handling properties compared to
RTC matrices during the cryo-SEM sample preparation, as the RTC matrices were
observed to be physically breaking apart during the loading of samples on SEM sample
stage, while the oligomer matrices remained intact. The low mechanical integrity of RTC
matrices has been observed previously [120] and could be due to the poor mechanical
stiffness of telocollagenic formulations [238, 248] that the RTC matrices are claimed to
be made of [249]. Previous reports have shown that oligomer matrices were significantly
stiffer than their telocollagenic counterparts when polymerized at the same collagen
concentration, owing to increased interfibril branching [177] [238, 248]. Thus, the altered
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packing and alignment of collagen molecules that occurs in the presence of covalently
cross-linked molecules (oligomers) during self-assembly may have resulted in increased
interfibril branching and distinct hierarchical architecture [120].
The release mechanisms that were inferred from Weibull fit-based parameters indicated
differences in release from oligomer and RTC matrices in both absence and presence of
collagenase. In the absence of collagenase, release from oligomeric matrices emulated
diffusion through normal Euclidian substrate while that through RTC matrices was
similar to diffusion through a disordered substrate (Figure 9). Similar differences were
observed in presence of collagenase as well, with oligomer showing diffusion through
disordered substrate, but RTC matrices showing complex release mechanism. However,
the mechanisms in RTC case had to be interpreted carefully, due to the poor Weibull fit
(R2) values observed. These could be attributed to the rapid degradation of RTC matrices
causing reduction in sampling availability and thereby affecting the Weibull fitting of the
data [250].
In general, RTC matrices exhibited significantly faster diffusion compared to that shown
by oligomer matrices. Such a rapid release from conventional non-crosslinked collagens
has been previously observed. For example, basic fibroblast growth factor (bFGF) was
released from non-crosslinked collagen matrices during the first 6 hours [251]. Similarly,
a collagen sponge incubated with rhBMP-2 (~26 kDa) solution released 55% of the
protein in 1 h and 100% in 2 days [252].Larger molecule Riboflavin (376.36 g/mol) was
also released in a short duration of 16 hours from collagen sponges [253]. Implantation
of a gentamicin-impregnated collagen sponge Garamycin in horses resulted in peak
concentration of gentamicin within 3 hours [254]. Considering these burst release
examples from conventional collagen, the ability of oligomeric collagen to provide both
size-dependent and sustained molecular release in both the absence and presence of
collagenase appears impressive. These results indicate the potential of these unique
building blocks in forming a multifunctional drug delivery platform capable of delivering
a wide range of molecules without the need for exogenous agents.
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2.4.2 Tuning microstructure and molecular release properties of oligomer fibril
matrices
The ability to provide sustained drug release is not adequate for the success of a drug
delivery implant in vivo. Implants should be tunable in terms of their mechanical,
microstructural, and molecular release properties to match tissue regeneration rates, as
these rates can vary based on the location of soft tissue damage or its healing stage, as
well differences in an individual’s age, dietary intake, healing rate, and lifestyle-related
factors [255]. Despite wide research and promising results of collagen-based materials in
improving therapeutic efficacy and delivery [3, 4, 66], the inability of the collagen based
systems to provide tunable release is still a major limitation restricting its clinical utility.
Challenges in tuning molecular release from conventional collagen matrices stem from
open weave structure of collagen [4]. This problem is compounded by the poor
characterization of conventional formulations in terms of their molecular composition
and inability to fully capitalize on the inherent self-assembly or polymerization capacity
of collagen leading to weak mechanical integrity and cursory control over physical and
molecular release properties [14, 15, 116, 248]. Hence, to tune molecular release from
collagen, it has been necessary to rely on methods such as exogenous crosslinking,
mixing with another polymer phase, covalent or non-covalent bonding, or sequestration
in a secondary matrix as listed in Table 1. However, such steps not only increase the
complexity of the system, but also alternative microstructure of collagen [256, 257].
Therefore, a combination of improved collagen formulation and a tuning strategy that
does not alter physiologically relevant properties of collagen is desirable to improve
tunable molecular delivery from collagen.
Here, we addressed this problem with the use of self-assembling oligomer building
blocks that have been shown to retain physiologically relevant crosslinks [14] and have
been used to predictably and reproducibly control fibril- and matrix-level physical
properties for the creation of 3D in-vitro tissue systems [116, 125] while illustrating
robust physico-mechanical properties [14, 120, 177, 179, 238].

To tune molecular

release using these novel oligomer building blocks, we applied two strategies that can
preserve the physiologically relevant microstructure of collagen: 1) modulating the
polymer composition through change in compositional building blocks of collagen; and
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2) densifying oligomer fibril matrices. While the first strategy offers an option of tuning
matrix microstructure, degradation, and release properties before polymerization of
collagen, the second strategy offers this tunability after polymerization.
2.4.3 Tunability by altering polymer composition
It has been known that modulation of collagen microstructure and composition affects
molecular transport from collagen-based materials [239-241, 258-260]. Literature survey
also reveals that collagen precursors (atelocollagen, telocollagen and oligomer) show
differences in mechanical [116, 120], physical [14], and biological properties owing to
the different interfibril branching capacity of the precursors. Here we wanted to extend
upon this work by studying the effect of these precursors on molecular release from
collagen. First, we observed microstructural differences between oligomer, telocollagen
and atelocollagen (Figure 10A), that could be attributed to the interfibril branching
differences observed between these precursors previously. For example, Kreger et al.
[120] observed slight decrease in fibril density of atelocollagen based PureCol matrices at
0.5 and 2 mg/ml concentrations, and Whittington et al. observed increased interfibril
branches in oligomer when compared to telocollagen (also called monomer) at 1.5 mg/ml
collagen concentration [115]. When effect of this changing microstructure between
oligomer, telocollagen and atelocollagen was studied on molecular release kinetics,
oligomer matrices were found to provide the slowest release kinetics in contrast to the
fastest release kinetics provided by atelocollagen matrices, under both absence and
presence of collagenase conditions (Figure 10B and C respectively). These differences in
molecular release can be attributed to the differences in proteolytic degradation (Table 4)
as well as differences in ultrastructure between oligomer and atelocollagen fibril
matrices. Telocollagen showed release characteristics slightly faster than oligomer, but
they were not statistically significant. As a result, oligomer and atelocollagen precursors
displaying slowest and fastest release kinetics were identified as viable candidates for
further tuning of molecular release from collagen.
Upon further mixing of oligomer and atelocollagen in different ratios, both matrix
microstructure and molecular release were found to be affected (Figure 12). Increases in
oligomer percentage was correlated with improved fibril thickness and fibril inter-
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connectedness (Figure 12A). Furthermore, increase in oligomer percentage within the
mixed matrices led to an increase in matrix stiffness, an increase in polymerization rate,
and a decrease in polymerization half time (Figure 11) that is in agreement with previous
reports that studied effect of increasing oligomer content in mixed matrices consisting of
oligomer and telocollagen [123]. These effects can be attributed to an increase in
interfibril branching [179].
Molecular release was also modulated through the mixing of oligomer and atelocollagen
in different ratios (Figure 12 B and C). In absence of collagenase, variations in release
profiles for both small and large FITC-dextran were obtained - ranging from burst to
sustained - by increasing the oligomer percentage within mixed matrices (Figure 12B).
This tunability, especially for small molecule 10 kDa, cannot be achieved with the use of
conventional collagen formulations in the absence of secondary retention mechanisms
[72],[103, 193]. The presence of collagenase further exaggerated this tunability,
especially for large molecules (2000 kDa FITC-dextran). This was most likely due to the
differences in proteolytic degradation of oligomer and atelocollagenic matrices that
contributed to existing differences in diffusional release. In general, molecular release of
2000 kDa FITC-dextran was slower than that of 10 kDa FITC-dextran, which is in
agreement with previous reports documenting increased diffusional hindrance for large
molecules when compared to small sized molecule [193, 261]. Collectively, these results
demonstrate effectiveness of mixing oligomer and atelocollagen precursors in tuning
molecular release as well as matrix degradation.
2.4.4 Tunability via densification of oligomer fibril matrices
Increasing fibril density or collagen concentration is another way to controls
molecular release as this approach decreases matrix porosity [4, 5]. This strategy has
been previously applied to control release of a number of molecules from collagen-based
materials. For example, by varying collagen content from 1.5% to 2.0% and 2.5 %,
FITC-coupled pexiganan release from collagen was extended from 24 h to 48 h and 72 h
respectively [262]. Lauzon et al. observed that modulating the concentration of collagen
hydrogels from 1.5 to 4.5 mg/ml affected pBMP-9 interaction with collagen and its
molecular release [263]. Fujioka et al. [73, 264, 265]observed sustained release of various
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proteins by increasing collagen density using methods such as ethanol immersion and air
drying. While these methods were successful in tuning molecular release, an associated
concern is decrease in the porosity to an extent that cell migration and proliferation can
be hampered [4].

Therefore, it is important to maintain a balance between matrix

porosity and collagen concentration.
Another problem associated with densifying collagen matrices is the viscosity of
collagen. Practically, due to the high viscosity, formulating collagen solutions at
concentrations above 10% has been very difficult [70, 73, 174]. Therefore, alternative
methods such as reverse dialysis[266], continuous injection and evaporation [267] and
centrifugation followed by polymerization [268] have been attempted to increase the
density of collagen. Unfortunately, these methods can require weeks to months to prepare
and can result in matrices with varying microstructures[116], and limited cell migration
or infiltration into the densified material [269, 270].
To overcome these limitations, and to better approximate the structural hierarchy
and mechanical properties of mature tissues, Blum et al. recently used the method of
confined compression on oligomeric collagen matrices to yield high fibril density
matrices with high cell viability [116]. Due to the success of this technique in
maintaining collagen microstructure and physiological relevance (D banding pattern)
even at high fibril density, we decided to apply it for molecular release. As such, high
density oligomer fibril matrices (20 and 40 mg/ml) containing either 10 or 2000 kDa
FITC-dextran were formulated from low fibril density matrices (3 mg/ml) through
irreversible removal of the interstitial fluid component in a confined format.
The resultant matrices showed an increase in fibril density (Figure 13A) and mechanical
integrity, in agreement with previous reports, where increasing collagen concentration
has been correlated with increase in fibril density and a concomitant increase in matrix
stiffness [14, 116, 120, 271, 272]. Oligomers, as distinct collagen building blocks form
more elastic and stiffer fibrillar and suprafibrillar assemblies by fostering formation of
interfibril branches [116] [14] compared to conventional collagens. Since these factors
are known to affect molecular transport from collagen, we hypothesized that molecular
release can be affected through the use of densified oligomer matrices.
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Indeed the densification of matrices from 3 mg/ml to 20 mg/ml and 40 mg/ml
significantly extended molecular release profiles and increased retention of both 10 kDa
and 2000 kDa FITC-dextrans (Figure 13B & C). In absence of collagenase, release
through both low and high fibril density matrices was found to be diffusion-based, as
indicated by Weibull-fit based parameters. When matrix density was increased from 3
mg/ml to 20 mg/ml, both 10 kDa and 2000 kDa FITC-dextran release was significantly
prolonged. However, upon increase of fibril density from 20 to 40 mg/ml, only 2000 kDa
FITC-dextran release was further extended, thus elucidating that both fibril density and
molecular size influenced release kinetics.
Further exposure of the collagen matrices to 10 U/ml collagenase amplified the
molecular release differences between low and high fibril density matrices. This
exaggeration in molecular release differences can be a result of differences in proteolytic
degradation of matrices. Such differences in the proteolytic degradation of low and high
fibril density oligomer matrices were previously observed by Blum et al. [116]. In line
with these results, slowest degradation based molecular release was observed from 40
mg/ml matrices, followed by that through 20 mg/ml and 3 mg/ml matrices. Thus, as fibril
density of matrices was decreased, the degradation based molecular release was
enhanced. Collectively, these results show that by varying the fibril density of oligomer
matrices, we could provide a broad range of tunability for both small and large sized
molecular release, both in the absence and presence of collagenase.
2.4.5 Tuning proteolytic degradation based molecular release
Conventional collagen implants with minimal or no crosslinking degrade so quickly that
the scaffolds disappear before the host tissue can deposit its own ECM [273]. Therefore,
there is a need to control degradation of implants [274] as well as their degradation-based
molecular release kinetics. However, collagenase levels vary in normal versus
pathophysiological states and also at various locations in vivo [187, 188]. Moreover, the
level of collagenase varies according to age of the wound [189]. Therefore, it is important
for collagen-based implants to be tunable in terms of their molecular release under
varying collagenase levels[190] [191].
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While many studies have documented controlled degradation of collagen-based
materials [275, 276] and drug delivery devices [277-279], these were conducted at only
one level of collagenase. Literature about collagen-based drug delivery devices providing
controlled degradation at varying collagenase levels [187, 277] is sparse. Moreover, data
for enzymatic activity is limited. Therefore, to choose appropriate levels of collagenase in
demonstrating tunable proteolytic degradation based molecular release, we reviewed
literature describing in-vivo concentrations of collagenase [184] [192] [187] and selected
collagenase levels of

100 U/ml and 10 U/ml as representative values of matrix

metalloproteinase equivalents present in chronic and acute wounds. The collagenase at
the levels of 100 U/ml and 10 U/ml was then used to compare molecular release in their
presence to that in absence of collagenase (Figure 14). From Figure 14A and C, it can be
observed that the low collagenase level and higher fibril density provided maximum
molecular retention. This can be attributed to a proportionate decrease in enzymatic
breakdown of collagen with decreasing collagenase concentration [192] and enhanced
resistance to proteolytic degradation with increased fibril density [116]. Furthermore, the
interaction plot Figure 14B showed that collagenase level, fibril density as well as the
interaction of collagenase and fibril density with each other had a significant effect on
molecular release. To find out which of the two factors- collagenase level or fibril density
had a more dominant effect on tuning molecular release, we plotted a contour graph
(Figure 14C) where the changing gradient of contour colors from light grey to dark grey
indicated increasing T50% values. The color change was fastest on x axis (fibril density)
than on y axis (collagenase level), indicating the dominant role of fibril density parameter
in affecting T50% values, compared to role of collagenase level. Amongst all fibril
density matrices, 40 mg/ml matrices exhibited the greatest resistance to collagenase and
therefore displayed the most extended release (Figure 15).
Weibull function-based modeling showed the effect of fibril density and collagenase
level on the release mechanisms. Interestingly, 40 mg/ml matrices showed different
release mechanisms at each collagenase level (Figure 14A), i.e. diffusion with 0 U/ml
collagenase, diffusion+degradation in presence of 10 U/ml, and first order release in
presence of 100 U/ml. These results offer key information about the behavior of different
matrix fibril densities in response to different proteolytic levels, conveying the potential
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of oligomeric collagen in providing proteolytic resistance and control over diffusional
release, even in the presence of high levels of collagenase.

2.5

Conclusion

There is a significant challenge in the design and manufacture of multifunctional biograft
materials from conventional collagen due to their poor mechanical properties, rapid
proteolytic degradation, and cursory control over physical properties and molecular
release profiles.
This work attempts to address these limitations by the application of novel selfassembling collagen-fibril biograft materials. More specifically, collagen polymers
specified by their intermolecular crosslink composition and self-assembly capacity were
used to customize and design materials in terms of 1) collagen fibril microstructure and
mechanical properties, and 2) proteolytic degradability, collectively defining overall local
molecular release profiles. Results showed that by altering collagen fibril-level features
that dictate matrix-level microstructure and degradation properties, collagen-based
platforms were successfully formed for tunable delivery of both small and large sized
molecules.

With its uniform, highly branched and porous microstructure, coupled with its high
mechanical integrity and high tunability, we believe the self-assembling collagen-based
matrices have a clear advantage over conventional collagens, increasing their potential to
transition into clinically successful drug delivery products.
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CHAPTER 3.
APPLICATION OF COLLAGEN FIBRIL
BIOGRAFTS FOR ENHANCING LOCAL VASCULARIZATION
IN AN IN-VIVO CHICK CHORIOALLONTOIC MEMBRANE
(CAM) MODEL

3.1

Introduction

As a result of their difficult-to-heal nature, complex and chronic wounds, such as skin
ulcers, are increasingly impacting the health and life-style of our society and remain a
major clinical challenge. At present, 6.5 million people are affected by chronic wounds in
the United Stated alone [17] with an estimated 25 billion dollars spent annually to treat
these patients. This societal and economic burden continues to escalate largely owing to
increasing health care costs, an aging population, and a higher incidence of diabetes and
obesity [19].
Chronic wounds fail to heal because of an imbalance between extracellular matrix (ECM)
deposition

and

degradation,

impaired

cell recruitment,

and

lack

of

essential

neovascularization [28]. Normal healing of acute wounds represents a multi-step process
beginning with hemostasis and inflammation during the acute stages of healing, followed
by phases of robust cellular proliferation, ECM deposition, matrix remodeling, and
ultimately scar formation [17, 24]. However, in chronic wounds, the dynamic spatiotemporal interaction between endothelial cells, angiogenesis factors, and surrounding
ECM proteins is impaired [280], causing the wound to be in a permanent inflammatory
state [16] and display increased proteolytic activity contributed by excessive production
of matrix metalloproteinases (MMPs) [25, 26]. MMPs in turn break down components of
the ECM and inhibit growth factors that are essential for tissue synthesis and regeneration
[27]. Therefore, promoting recreation of the natural type I collagen fibril scaffold while
fostering rapid and functional neovascularization and tissue regeneration at wound site, is
pivotal to restoration of healing of chronic wounds.
As such, many efforts have been lately focused on the design and development of
collagen based biomaterials that can provide the structural and mechanical support for the
cellular infiltration and growth, while promoting the neovascularization at the wound site.
A number of advanced wound dressings, and skin substitutes have been introduced in the
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wound care market during the last decades [32, 34-39, 281]. However, no general
satisfactory clinical solution has been achieved to date [32, 282] because of undesirable
outcomes of these products, including inflammation mediated healing leading to scar
formation rather than tissue regeneration, slow neovascularization and cellularization and
a need for multiple applications that adds to patient discomfort, pain and healthcare cost.
Therefore, there is an acute need to overcome these problems through improved design of
multifunctional collagen biografts.
An alternative of combining growth factors into collagen could potentially address the
issue of slow vascularization and tissue regeneration through collagen based products,
[59-61], since growth factors play important regulatory role in

tissue repair and

regeneration in wounds (e.g. granulocyte-macrophage colony stimulating factor (GMCSF), platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF),
and basic fibroblast growth factor (bFGF)) [283]. Among the various growth factors,
VEGF is one of the most potent proangiogenic growth factors that significantly impacts
wound vascularization [284]. VEGF is a 45 kDa heterodimeric heparin-binding protein,
acting as a potent mitogen (ED~50: 2-10 PM) for micro and macrovascular endothelial
cells derived from arteries, veins and lymphatics, inducing their proliferation, migration
and tube formation [285]. VEGF level rises in normal wound repair, leading to a vigorous
angiogenic response, however, in chronic, nonhealing wounds, active VEGF falls to
abnormally low level, due to possible degradation of VEGF by the excessively high
protease activity in chronic wounds [286]. Poor vascularization which is a hallmark on
chronic wounds such as diabetic foot ulcers, can therefore benefit by the use of VEGF
delivery [287].
Lately, the important role of ECM in coordinating VEGF signaling in wounds in-vivo has
come to light [61, 92]. ECM localizes VEGF via heparin and heparan sulphate
proteoglycan (HSPG) molecules [282, 288]. Heparin or HSPGs have highly negative
charge (approximately 75) due to the prevalence of sulfate and carboxylate groups, that
endows heparin with an ability to electrostatically bind to many basic biomolecules,
including proteins, growth factors, proteases and chemokines [289]. The binding of
VEGF to heparin occurs through such electrostatic interaction (affinity binding) [290].
Heparin then facilitates binding of VEGF to its two receptors Flt-1/VEGFR1 and Flk-
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1/VEGFR2 through binding and stable complex formation with neuropilin (NRP)-1
coreceptor, resulting in phosphorylation and further signaling activity of VEGF [291],
such as providing essential stimulatory cues to initiate vascular branching [292] as well
as endothelial tip cell filopodia emission [293]. Heparin binding thus regulates the
physiological effect of VEGF on endothelial cells [294-296]. Heparin plays another
important role of enabling the ECM to act storage depot of growth factors. Because of
affinity of heparin for type I collagen in ECM, heparin retains VEGF in ECM, protects it
from proteolytic degradation [297-300], and allows prolonged presentation of VEGF to
cells [301, 302].
Inspired by this role of ECM, heparin and VEGF in providing coordinated biochemical
and biomechanical cues for in vivo vascularization, and due to well documented affinity
of heparin for VEGF and ECM [303-306], many systems have incorporated heparin
based interactions in collagen for loading of VEGF [64, 98, 307-311] previously.
However, these systems consisted of monomeric collagen formulations that were
chemically crosslinked for retention of heparin. As a result of chemical crosslinking,
VEGF had to be loaded in the last step of formulation, so that chemicals used for
croslsinking would not destroy the bioactivity of VEGF. VEGF was then loaded typically
either through immersion of the formulated matrices into VEGF solution or through
impregnation of VEGF in the matrices, both of which can lead to low VEGF loading
efficiency. Furthermore, VEGF used in these formulations is VEGF 165 that binds to
heparin through

positively charged lysine and arginine residues encoded by exon 7 of

VEGF gene [312]. However, it is also known that VEGF 189 isoform contains in addition
to the amino acids encoded by exon 7, 24 amino-acids that are derived from exon 6,
constituting yet another heparin binding domain [313]. As a result, VEGF 189 shows
stronger affinity for heparin due to presence of two heparin binding domains [314, 315]
and these binding sites are reported to be distinct from VEGF's receptor-binding domain
[316].
Considering the stronger affinity of VEGF189 for heparin, and binding affinity of
heparin for type I collagen self-assembling molecules, we decided to engineer a unique
self-assembling collagen based biograft system that can act as a storage depot for
VEGF189 and promote vascularization of the implant in an accelerated manner (Figure
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16).

A key element of our design approach is the application of type I collagen

oligomers, which represent a soluble collagen formulation capable of self-assembling
into collagen-fibril matrices with higher-order interfibril associations. As such, the
supramolecular assembly of oligomers supports the creation of collagen–fibril matrices
with a broad range of structural and mechanical properties (specified by fibril density and
matrix stiffness) beyond those that can be achieved with conventional collagen
monomers, such as atelocollagen, and telocollagen [14, 120, 121]. Heparin was added to
oligomer molecules in selective quantities that did not alter the oligomer molecule selfassembly and viscoelastic properties and VEGF189 was added in quantity lower than
heparin. Through single step admixing, the collagen containing heparin and VEGF 189
was self-assembled. This process relied on simple affinity based retention of heparin and
VEGF in the polymerized collagen system, without the use of any exogenous chemical
crosslinking, which is in stark contrast to current approaches that rely on chemical
crosslinking based immobilization of heparin or VEGF in the collagen scaffolds [64, 98,
251, 310, 317, 318].
Thus, the design of collagen implants in our study differs from previous systems in the
following aspects: 1) Application of oligomeric collagen as opposed to monomeric
collagen formulations; 2) Use of lower quantities of heparin that do not alter collagen
polymerization properties; 3) Use of VEGF189 instead of VEGF165 due to its stronger
heparin binding affinity; and 4) pure affinity-based retention of heparin in collagen as
opposed to chemical immobilization.
We hypothesized in this study, that through affinity based binding of heparin and VEGF
in self-assembling oligomer implants, the vascularization as well as cellularization
potential of collagen scaffolds can be improved for tissue engineering and tissue
regeneration applications. To test this hypothesis, we designed low and high fibril density
oligomer implants with and without heparin and VEGF molecules, and evaluated their
functionality

in
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Figure 16: Graphical representation of design strategy used in this study. Affinity of
heparin for collagen and VEGF189 was exploited to retain VEGF in self-assembled
oligomer matrices. Chicken egg chorioallantoic membrane (CAM) assay was used to test
the functionality of implants.
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3.2

Methods

3.2.1 Preparation of soluble collagen formulations
Oligomeric self-assembling type I collagen was derived from market weight pig
dermis, as described previously [120]. Extracted collagen was lyophilized for storage and
dissolved in 0.01 N hydrochloric acid (HCl) for use. Oligomer collagen solution was
rendered aseptic by exposure to chloroform overnight at 4°C and was standardized based
upon purity as well as polymerization potential, as described in ASTM 3089-14 [163].
Here, polymerization potential is defined as the relationship between the shear storage
modulus (G’) of the polymerized matrices and the collagen content of the polymerization
reaction [14, 120]. The oligomer collagen solution was diluted with 0.01 N HCl to
achieve desired concentrations and neutralized with 10X phosphate buffered saline (PBS)
and 0.1 N sodium hydroxide (NaOH) to achieve pH 7.4 [120]. Neutralized solutions were
kept on ice prior to induction of polymerization by warming to 37oC.
3.2.2

Polymerization kinetics and viscoelastic properties of collagen

Oligomer collagen polymerization kinetics and viscoelastic properties were measured in
the presence of 0, 0.5, 1, 5, 10 or 100 μg/ml heparin sodium salt (H3149, Sigma Aldrich,
St. Louis, MO, USA), using an AR2000 rheometer (TA Instruments, New Castle, DE)
equipped with stainless-steel 40 mm-diameter parallel plate geometry [14, 120].
Oligomer solutions (3 mg/ml) with or without heparin were neutralized and pipetted onto
the Peltier plate. Upon lowering the geometry, the Peltier plate temperature was
maintained at 4o C for 5 minutes and then increased to 37o C for 15 minutes to induce
oligomer polymerization. Time-dependent changes in shear storage modulus (G’) were
measured at 1% controlled oscillatory strain. Each matrix formulation was tested five
times (N=5).
3.2.3

Formation of heparinized oligomer implants with and without VEGF

3.2.3.1 Low fibril-density implants
In total, 4 implant groups were prepared with 3 mg/ml oligomer collagen, namely
i) Coll (Oligomer collagen alone); ii) Coll + VEGF (Oligomer collagen + 0.5 μg/ml
VEGF189); iii) Coll + Hep (Oligomer collagen + 1 μg/ml Heparin); iv) Coll + Hep +
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VEGF (Oligomer collagen + 1 μg/ml Heparin + 0.5 μg/ml VEGF189). Heparin and/or
recombinant human VEGF 189 (Abcam, Cambridge, MA) were solubilized in 10X PBS
in desired quantities and admixed with oligomer. Solutions were then pipetted into 48well tissue culture plates (Corning, Corning, NY) at 0.25 ml per well, followed by
induction of polymerization by warming at 37oC overnight. In some instances, implants
were washed in sterile 1X PBS by gentle rotation on microplate shaker (ThermoFisher
Scientific, Waltham, MA) for 24 hrs. All references of admixing VEGF 189 in this work
are henceforward referred to as simply "VEGF" addition.
3.2.3.2 High fibril-density implants
High-density oligomer implants were created using confined compression as
described previously [116]. Briefly, neutralized oligomer of concentration 4.56 mg/ml
(with or without 1 μg/ml heparin and 0.5 μg/ml VEGF) was prepared on ice, and pipetted
into 48-well tissue culture plate at 1.1 ml per well. The plate was incubated overnight at
37oC to induce polymerization of oligomer. Polymerized matrices were then densified 4.4
X, using a porous polyethylene platen (50 µm pore size) at 6 mm/min to final thickness
of 0.26 cm, yielding 0.25 cm3 densified collagen implants at 20 mg/ml concentration.
Based on the addition of heparin and VEGF, the resultant 20 mg/ml, high-density
implants were classified into 4 groups, similar to those in low-density implants. Washing
of select implants was conducted as described for low-density implants.
3.2.4 Characterization
3.2.4.1 Assessing spatial distribution and retention of heparin in oligomer
To visualize heparin localization within matrices, fluorescein conjugated heparin
(FITC-heparin, H7482, Fisher Scientific, Carlsbad, CA) was dissolved in 10X PBS and
used to neutralize 3 mg/ml oligomer collagen. FITC-heparin containing oligomer
solutions were then pipetted on Lab-Tek chambered cover glass slides (Nunc, Thermo
Fisher Scientific, Rochester, NY) and polymerized overnight in a 37oC incubator.
Samples were washed for 24 h with 1X PBS and compared with unwashed samples for
FITC-heparin retention.

Confocal microscopy was performed on implants using an

Olympus Fluoview FV1000 confocal system adapted to an Olympus IX81 inverted
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microscope (Olympus, Tokyo, Japan). Image Z-stacks (10 µm depth; 0.5 µm step size)
from at least three random locations within each matrix were taken with a 60X water
immersion objective at 4X digital zoom using 488 nm excitation and 510-530 emission.
3.2.4.2 Quantifying heparin retention in collagen
The amount of heparin in collagen implants was quantified using the 1,9dimethylmethylene blue (DMMB) assay [319]

adapted for microplate reading [320].

Heparinized oligomer constructs were prepared as described above. All 3 mg/ml washed
and unwashed collagen implants were digested with an equal volume (250 μL) of a
digestion buffer consisting of 1 mg/ml papain, 6.9 µg/ml of sodium phosphate
monobasic, 0.326 µg/ml of N-acetyl cysteine, and 0.76 µg/ml of EDTA tetrasodium salt
(Sigma-Aldrich, St. Louis, MO) dissolved in H 2O. Digestion was performed at 65°C for
24 hrs. DMMB dye was added to papain-digested samples and absorbance measured at
525nm and 595nm wavelengths using a spectrophotometer (Molecular Devices
Spectramax M5, Sunnyvale, CA). Sample heparin concentrations were then determined
from a standard curve generated with known heparin concentrations [321]. All standard
solutions and samples were prepared in triplicate and assayed three times (N=3, n=3).
3.2.5 Chicken chorioallantoic membrane (CAM) vascularization assay
The CAM assay was performed as described elsewhere [322, 323]. Briefly,
fertilized White Leghorn chicken eggs (Poultry Unit, Purdue University Animal Science
Research Center) were horizontally positioned and incubated at 38

o

C under 58% + 2%

relative humidity in an egg incubator equipped with a turner which automatically rotated
the eggs 5 times/day until day 7 [324]. On day 8, a window of approximately 2.5 cm
diameter was created using a Dremel tool (Dremel, Racine, WI) equipped with a cutting
disc. The window was sealed with adhesive tape and eggs were returned to the incubator.
On day 9, collagen implants were inserted on the CAM of viable eggs. The implant
groups consisted of i) CAM alone; ii) CAM with washed 10 mm diameter paper disc
(Sigma-Aldrich, St. Louis, MO); iii) Absorbable collagen dressing Helicote (Integra Life
Sciences, Plainsbboro, NJ) - referred to in this work as Integra collagen; and iv) 3 mg/ml
oligomer. CAM was digitally photographed on day 9 and day 12 after completion of the
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assay. In another set of experiment, washed low density (3 mg/ml) and high density (20
mg/ml) implants (Coll; Coll + VEGF; Coll + Hep; and Coll + Hep + VEGF) were
inserted on CAM to determine effect of heparin and VEGF189 infused oligomer implants
on vascularization. Post 3 days of implantation, on embryonic day 12, all CAM samples
were photographed and fixed in situ using 4% paraformaldehyde as per to protocol [325].
Each experimental group was assigned at least 6 viable eggs (N=6-8). The timeline of
CAM assay is shown in Figure 17.

Figure 17: The schematics of CAM assay timeline (A). The pictorial visualization of
assay steps between embryonic day (ED) 9 and 12 is shown in part B. Image 1 in part B
shows a window cut open in egg on ED8, image 2 shows implantation of 3 mg/ml
oligomer implant on ED9, and image 3 shows the status of implant on ED12.
3.2.6 Scoring vascular response and contraction of implants used in CAM assay
The vascularization response was determined using two scoring schemes to compare
photographs from day 12 to those from day 9. A “vascular score” was determined by
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scoring the vessel density and distribution (5 = strong, 1 = weak) around the collagen
implants on CAM [326], by observing top view as shown in Figure 18. Similarly, vessel
tortuosity and abnormality in CAM was scored on a scale of 1 to 5 (5=
irregular/tortuous/brush like, 1 = normal), based on observation of irregular vessels or
fine brush-like vessels on CAM. Percent contraction of implant area (mm2) was also
quantified based on the differences between implant area observed on day of insertion
(day 9) and day of CAM harvest (day 12 or 18).

Figure 18: Implant evaluation for vascular response. (A) Implants were evaluated for
their vascularization ability by scoring CAM vessel response from top view, before
performing histological staining. (B) Drawings representing examples of different
vascular responses in CAM assay. A ranking method from 1-5 was used for semiquantitative scoring of vessel density and distribution of CAM around the implanted
inserts.
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3.2.7 Histology
The fixed, excised CAM tissue samples were analyzed with the help of Purdue Histology
Research Lab. Samples were routinely processed, sectioned and stained for Hematoxylin
and Eosin. All samples were sectioned at 5um thickness using a rotary microtome. Slides
were imaged with a Nikon Eclipse E200 optical microscope using 40, and 4X objective
to visualize CAM cells and capillaries invading the implants.
3.2.8 Statistical Analysis
The differences between all experimental groups were determined using ANOVA
followed by a post-hoc Tukey test with a 95% confidence interval, except for identifying
difference between heparin content in washed versus unwashed matrices. For that
purpose, a two-sample Student’s T-Test with a confidence interval of 95% was used. For
all tests, p<0.05 was considered significant. All the groups were analyzed using Minitab
16.0 statistical software (Minitab Inc., State College, PA).

3.3
3.3.1

Results
Upto 1 µg/ml heparin does not affect oligomer polymerization kinetics and
viscoelastic properties

Previous studies have shown that heparin affects self-assembly or polymerization of
conventional monomer formulations (telocollagen and atelocollagen),

altering matrix

consistency and viscoelastic properties [327]. Here we determined the effect of heparin
on oligomer collagen polymerization and viscoelastic properties and defined heparin
levels that do not alter matrix physico-mechanical properties. Based on the oscillatory
shear based tracking of rate of change of the storage modulus (G') of oligomer containing
different amounts of heparin (Figure 19A), we found that the polymerization kinetics of 3
mg/ml oligomer was statistically similar for heparin concentrations up to 10 μg/ml
(Figure 19B). At 100 µg/ml a significant decrease in polymerization half time was
observed (Figure 19B). Evaluation of heparin addition on matrix viscoelastic properties
(Figure 19B) showed that addition of 0.5 and 1 μg/ml had no significant effect; however,
addition of heparin at 5, 10, and 100 μg/ml resulted in a significant lower G' (p<0.05,
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N=5). Collectively, these results confirmed that addition of upto 1 μg/ml heparin does not
alter oligomer polymerization and viscoelastic properties.

Figure 19: Effect of heparin on oligomer matrix polymerization kinetics and
viscoelastic properties . (A) Time-dependent changes in shear-storage modulus of 3
mg/ml oligomer with 0, 0.5, 1, 5, 10 and 100 μg/ml of heparin. At t=0, temperature was
raised to 37°C to induce matrix self-assembly. (B) Polymerization half-times represented
by P 50% (mean±SD), and shear storage modulus (G’, Pa) after 15 minutes of
polymerization (mean±SD), were quantified from the curves in (A). Each sample was
tested five times (N=5). Letters in P 50% and G' column in (B) indicate statistically
different experimental groups as determined by Tukey-Kramer range test (N=5, p<0.05).
3.3.2 Heparin colocalizes with oligomer fibrils and is retained after washing
Heparin is known to bind to type I collagen monomer formulations with high affinity
[328-330] and its effect on collagen fibril size and self-assembly has been studied
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extensively in the past [327, 330-333]. Here, heparin localization and retention within
self-assembled oligomer matrices was measured using confocal microscopy and
established DMMB assay.

Figure 20: Heparin in oligomer matrix is retained after washing. The amount of
heparin retention was confirmed by 1, 9- dimethylmethylene blue (DMMB) assay (A).
Asterisk (*) indicates significant difference based on two sample student's T test (N=3,
n=3, p<0.05). Fluorescein conjugated heparin (FITC-heparin,) was loaded in oligomer
matrices at 100 μg/ml concentration to visualize heparin localization within matrices.
Image Z-stacks (10 µm depth; 0.5 µm step size) were taken with a 60X water immersion
objective at 4X digital zoom using 488 nm excitation and 510-530 emission. FITCHeparin was observed to be colocalizing in oligomer fibril matrix (3 mg/ml) (B) and was
found to be retained in matrix after 24 h washing (C). Scale bar in (B) and (C) represents
10 μM.
DMMB results indicated that

the concentration of heparin detected in unwashed

oligomer matrices with 0.5, 1, 5, 10 and 100 μg /ml heparin was 0.33, 1.19, 4.97, 11.84,
117.61 μg /ml respectively, and that in washed matrices was 0.29, 0.31, 1.17, 2.72, 24.74
μg /ml respectively (Figure 20, A). The increased amount of heparin retention with
increased heparin addition in oligomer matrices is in agreement with previous studies
[327, 332]. It was evident that while the washing step eliminated superficially attached
heparin at all concentrations (except for 0.5 μg /ml), at least 21% or higher amount of
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heparin was retained in all matrices. The exact percentage of heparin retained in washed
oligomer matrices containing 0.5, 1, 5, 10 and 100 μg /ml was 88.75%, 25.75%, 23.60%,
22.96%, and 21.03% respectively.
Corroborating results obtained using confocal imaging suggested that retained heparin
was associated and co-localized with formed collagen fibrils. (Figure 20, B and C).
3.3.3 Oligomer implants but not Integra collagen or paper disc exhibit enhanced
vascularization response in CAM after 3 days of implantation
To determine the capability of oligomer implants in inducing vascularization in vivo, we
implanted non-heparinized 3 mg/ml oligomer implants in CAM model between
embryonic day 9 and 12 and compared its evoked vascular response on CAM with that of
the CAM inserted without any sample, or with samples of paper disc, and commercial
Integra collagen sponge.
The visual appearance of these implants in their hydrated state before implanting on
CAM is shown in Figure 21. The paper disc, and the 3 mg/ml oligomer implants (Figure
21, A and C respectively) were observed to maintain shape integrity upon hydration,
however,

however, the Integra collagen implants (Figure 21B) could be easily deformed

into any shape upon hydration.

Figure 21: Visual appearance of implants used in testing vascular response in CAM
assay. Samples include A) Paper disc B) Integra collagen C) 3 mg/ml (low-density)
oligomer. Scale bar represents 5 mm length.
After implantation of oligomer, paper discs and Integra collagen samples for 3 days on
CAM, the blood vessel density and distribution of CAM surrounding the implants was
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scored using a semi-quantitative ranking system [326], as indicated in Figure 18 B. CAM
without any inserted sample served as a control (Figure 22, A). It was observed that
compared to the vascular response induced on CAM by the paper disc (Figure 22, B) or
the Integra collagen sponge (Figure 22, C), 3 mg/ml oligomer implants showed enhanced
vascular response to the implant (Figure 22, D). Among all the implant groups tested, the
3 mg/ml oligomer implants ranked significantly higher in their vascular score (p<0.05,
N=6). The Integra collagen showed no significant difference in their vascular score
compared to paper disc (Figure 22 E).

Figure 22: 3 mg/ml oligomer implants promoted enhanced vascular response of the
CAM around constructs compared to paper disc and Integra collagen samples .
CAM was implanted with various test sample groups represented by (A) No sample, (B)
paper disc, and (C) Integra collagen and (D) 3 mg/ml oligomer implant. Images were
taken with digital camera and represent top view of implants in situ. Scale bar= 5 mm.
(E) Vascular score calculated from top view images. Letters represent statistically
different groups determined by Tukey-Kramer range test (N=6-8, p<0.05). H&E staining
was performed on transverse histological sections of CAM implanted with F) no sample
G) paper disc H) Integra collagen I) 3 mg/ml oligomer. Black arrows in G) and H)
indicate empty spaces observed within the samples. Cells from CAM were found to
infiltrate the implanted Integra collagen H) and 3 mg/ml oligomer I). Scale bar represents
50 μM.
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Interestingly, both Integra collagen and oligomer implants contracted significantly
compared to the paper disc samples by day 3 of implantation. We suspected that this
contraction in part could have been contributed by cell infiltration as suggested by
Kilarski et al. [334]. To determine whether Integra and oligomer collagen samples indeed
supported cell infiltration, we performed histology on transverse sections of the CAM
implanted with Integra and oligomer collagen samples, after their in situ fixation.
Results of the H&E staining of transverse histological cross-sections of implants on CAM
are shown in Figure 22 (F-I). Both the oligomer (Figure 22I) and Integra collagen (Figure
22H) were observed to be infiltrated by cells from the CAM. However, the Integra
collagen showed highly porous structure indicated by black arrows in Figure 22H. Paper
disc also showed large empty spaces, however CAM cells failed to invade them (Figure
22G). These results also showed that the oligomer matrices were in close contact with the
CAM tissue, pointing tissue integrity, as opposed to the non-intact and highly porous
paper disc and Integra collagen samples on CAM tissue. Collectively, these results
showed that oligomer implants enhanced vascular response of CAM around the
constructs while maintaining cell infiltration within the constructs.
3.3.4 CAM vascular response around the implants is affected by contents and
density of oligomer fibril implants
After observing that 3 mg/ml oligomer alone induced a vascular response on CAM, we
decided to test if the functionality of oligomer implants in inducing vascularization on
CAM can be further enhanced through incorporation of heparin and VEGF. Heparin and
VEGF incorporation was also performed in high fibril density implants, since high fibril
density implants have been shown to add tunability and scalability in design of selfassembled collagen constructs, recapitulating the multi-scale structural and

functional

properties of soft tissues in vivo [116].
Therefore, we prepared 4 groups from both low fibril density and high fibril density
matrices for implantation on CAM, namely - i) Coll group, ii) Coll + VEGF group, iii)
Coll + Hep group, and iv) Coll + Hep + VEGF group. All groups were washed with 1X
PBS for 24 h in order to remove any unbound heparin and VEGF from oligomer matrix.
Our hypothesis was that the heparinized oligomer implants would retain VEGF longer
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due to affinity of VEGF for heparin, and as a result, induce more robust vascularization in
vivo.
After 3 days of implantation, results showed that densified 20 mg/ml constructs occupied
larger area on CAM (Figure 24 A-D) compared to the low fibril density 3 mg/ml implants
(Figure 23A-D), indicating the successful resistance to contraction as quantified in Table
5. Both low and high fibril density oligomer implants containing heparin and VEGF
together (Coll + Hep + VEGF group) exhibited a strong vascular response in the form of
a spoke wheel pattern (Figure 23 D and Figure 24 D), which can be attributed to the
successful retention of VEGF in the implant. Oligomer implants with heparin alone (Coll
+ Hep group) showed a weaker vascularization response (Figure 23 C and Figure 24 C),
with thinner vessels drawn towards the construct. The oligomer alone (Coll group)
showed only slight vascular response (Figure 23 A and Figure 24 A), while oligomer with
VEGF (Coll + VEGF) showed vascular response which was found to be abnormal due to
tortuous, fine-brush like or irregular appearance of the vessels (Figure 23 B and Figure 24
B).
Semi-quantitative scoring of CAM vascular response indicated that heparinized oligomer
implants induced higher vascularization than non-heparinized implants, in both the cases
of 3 and 20 mg/ml oligomer (Figure 23 E and Figure 24 E). Addition of VEGF to
heparinized oligomer implants further enhanced the vascularization capacity in 3 mg/ml
implants, but addition of VEGF to non-heparinized implants triggered an abnormal
vascular response showing tortuous and/or fine brush-like vessel formation, resulting in
high tortuosity score in both low and high fibril density oligomer implants (Figure 23 F
and Figure 24 F). This result highlighted the effectiveness of heparin in retaining VEGF
within the oligomer implant, leading to enhanced vascular response on CAM, as opposed
to tortuous vascular response observed with VEGF loaded implants that did not contain
heparin.
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Figure 23: Heparinization improved vascular response of CAM to low fibril-density
oligomer implants. (A-D) Top view of implants imaged in situ using digital camera.
CAM was implanted with 3 mg/ml collagen consisting of oligomer alone (A), oligomer +
0.5 µg/ml VEGF (B), oligomer + 1 µg/ml heparin (C), and oligomer + 1 µg/ml heparin +
0.5 µg/ml VEGF (D). Tortuous vessels were observed in VEGF loaded implants without
heparin (B), while VEGF-loaded implants with heparin showed a clear spoke-wheel
pattern of vascular response (D). Vascular score (E) and tortuosity score (F) calculated
from top view of implants. Scale bar represents 5 mm. Letters represent statistically
different groups determined by Tukey-Kramer range test (N=6-8, p<0.05).
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Figure 24: Heparinization of high fibril-density oligomer implants improved
vascular response of CAM while preventing abnormal vessel formation. CAM was
implanted with 20 mg/ml collagen consisting of oligomer alone (A), oligomer + 0.5
µg/ml VEGF (B), oligomer + 1 µg/ml heparin (C), and oligomer + 1 µg/ml heparin + 0.5
µg/ml VEGF (D). (A-D) top view of implants imaged in situ using digital camera. VEGF
loaded implants without heparin (B) induced tortuous vessel response, while VEGF
loaded implants with heparin induced normal and enhanced local neovascularization (D).
Scale bar= 5 mm. (E) Vascular and (F) tortuosity score calculated from top view. Letters
represent statistically different groups determined by Tukey-Kramer range test (N=6-8,
p<0.05).
The abnormal vascular response on CAM could have been likely a result of free, passive
diffusion of VEGF out of the oligomer. To confirm this speculation, we implanted 3
mg/ml oligomer implants containing VEGF alone (Coll + VEGF) on CAM immediately
after overnight polymerization without involving any washing step, and expected to see a
heightened tortuous response on CAM after 3 days of implantation. Results of this study
showed an increased chaotic, tortuous and fine brush like vessel response on CAM
(Figure 25 A). Further to confirm that this response was due to free diffusion of VEGF
alone was and that oligomer in conjunction with VEGF was not causing the abnormality,
we applied a paper disc soaked in VEGF on top of CAM, and post 3 day implantation,
found many major tortuous vessels on CAM (Figure 25 B).
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Figure 25: Uncontrolled release of VEGF results in tortuous / abnormal vascular
response on CAM. Black arrows indicate tortuous vessels while blue arrows indicate
fine brush like vessels and abnormality. Scale bar represents 5 mm
3.3.5 Collagen implant composition and fibril density modulate cell infiltration
and capillary formation within the implants
The evaluation of CAM vasculature from top view of the various low (Figure 23) and
high (Figure 24) fibril density implants informed us about the vascularization induced by
the implants around, but not within the constructs. Therefore, to evaluate the vascular
ingrowth within the low and high fibril density implants, we applied standard histological
analysis (H&E staining of tissue slices) capturing the cellular interaction between CAM
and the implant at their interface.
Results showed that both 3 mg/ml (Figure 26 A) and 20 mg/ml (Figure 26 E) oligomer
fibril implants supported some cell infiltration from CAM, however, the ingrowing cells
did not appear to be organized or aligned in a particular direction. The addition of VEGF
alone in oligomer implants did not seem to increase cell infiltration in low fibril density
(Figure 26 C) or high fibril density (Figure 26 G) implants, although it seemed to have
promoted higher vascularization on the surface of the CAM. In contrast, addition of
heparin alone to the oligomer resulted in enhanced cell infiltration with invading cells
aligned perpendicular to the CAM (Figure 26 B- low fibril density implants, and Figure
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26 F - high fibril density implants). Finally, the implants containing both heparin and
VEGF exhibited a dramatic increase in the cell infiltration while maintaining cell
alignment (Figure 26 D - low fibril density implants and Figure 26 H - high fibril density
implants). This group also showed remodeling of the collagen and most importantly,
exhibited functional capillary formation inside the implants.

The functionality of the

capillaries inside both the 3 mg/ml (Figure 26 D) and 20 mg/ml (Figure 26 H) implants
was evident from the nucleated red blood cells found inside the lumens of these
capillaries. The 20 mg/ml Coll + Hep + VEGF implants showed higher cell infiltration
and cell alignment into the collagen implant compared to the 3 mg/ml implant (Figure 26
H versus Figure 26 D), which could be on account of higher VEGF retention due to
increased fibril density. Collectively these histology-based results indicated that the
response of CAM vasculature both around and inside the implants was dependent on
presence of heparin and VEGF, as well as the fibril density of implants.
3.3.6 Summary of implant
formation

contraction,

cellular infiltration and capillary

Table 5 summarizes the contraction, cellular infiltration and capillary formation results
for all collagen implants tested in this study. Interestingly, the 20 mg/ml oligomer
collagen implants showed the least contraction, and it was not significantly different from
the contraction showed by Integra collagen. Integra implants showed cell infiltration but
not capillary formation. In general, the 20 mg/ml oligomer implants showed improved
mechanical integrity and resistance to contraction, compared to the 3 mg/ml oligomer
implants.
Cellularization and capillary formation was highest in the Coll+Hep+VEGF group of
both the 3 and 30 mg/ml 20 implants. The Coll + Hep group showed the second highest
cellular infiltration and capillary formation in both 3 and 20 mg/ml implant groups. The
cellular infiltration shown by Coll and Coll +VEGF group was lowest. It was evident that
the heparinized implants with VEGF promoted higher cellular infiltration inside implants
than the non-heparinized implants.
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Figure 26: Response of CAM cell invasion and vascularization varies according to
contents and density of oligomer implants . H&E staining of histological transverse
section of CAM implanted with 3 mg/ml (A-D) and 20 mg/ml (E-H) oligomer implants.
Samples consisted of oligomer alone (A&E), oligomer + 1 µg/ml heparin (B&F),
oligomer + 0.5 µg/ml VEGF (C&G), and oligomer + 1 µg/ml heparin + 0.5 µg/ml VEGF
(D&H). Heparinized VEGF-containing implants (D&H) promoted highest cellular
infiltration and capillary formation inside the implants while non-heparinized VEGFcontaining implants promoted capillary formation on CAM outside the implant periphery
(C&G). Black arrows indicate capillary formation. Scale bar represents 50 μM.
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Table 5: Comparison of contraction, cellular infiltration and capillary formation
inside different collagen samples

Sample

Final Area
2
(mm )
Mean ± Std.
Dev.

Cellular
invasion
inside
collagen

Capillary
formation
inside
collagen

++

-

A

+

-

AB

+++

+

ABC

++

-

AB

++++

+++

ABC

+

-

D

+

-

CD

+++

+

D

++

-

+++++

+++

% Contraction
Mean ± Std.
Dev.

Control
1. Integra

39.06 ± 13.75

A

50.27 ± 17.51

D

3 mg/ml Implants
1. Oligomer

15.78 ± 5.73

C

83.39 ± 6.03

2. Oligomer +
BC
18.08 ± 8.08
Heparin

80.97 ± 8.50

3. Oligomer +
BC
20.35 ± 5.38
VEGF189

78.59 ± 5.66

4. Oligomer +
Heparin +
VEGF189

83.26 ± 7.56

15.91 ± 7.19

C

5. Oligomer +
BC
VEGF189
19.30 ± 5.52
(unwashed)

72.56 ± 12.64

20 mg/ml Implants
1. Oligomer

45.38 ± 9.42

2. Oligomer +
Heparin

38.66 ± 9.64

3. Oligomer +
43.80 ± 10.79
VEGF189

A

A

A

4. Oligomer +
AB
Heparin + 32.31 ± 8.71
VEGF189

52.24 ± 9.91
59.31 ± 10.15
53.91 ± 11.35

66.00 ± 9.16

BCD
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3.4

Discussion

This study makes a contribution to the field of research aimed at enhancing and
accelerating the vascularization capabilities of collagen based biomaterials, for potential
use as engineered substitutes of tissues grafts. Inspired by the physiological role of
heparin in securing binding of VEGF to the ECM, we created self-assembled oligomer
matrices infused with heparin and VEGF that showed enhanced vascularization potential.
While heparin effects on collagen properties and vascularization has been studied in the
past [64, 98, 307-311], these studies involved heparin addition in conventional
monomers, not oligomers. Here, we report the use of oligomers for heparin based VEGF
retention

in

collagen

implants, and evaluate

their

functionality for

promoting

vascularization in vivo through a well-established CAM assay. Heparin and VEGF
incorporation in the implants was enabled through a single admixing step, and heparin
amount was chosen such that it did not alter physiological self-assembly of oligomer.
Furthermore, to enhance the mechanical strength and VEGF retention within the
implants, we increased the fibril density of the implants and determined its efficacy in
promoting microvasculature both around and within the implants. Both low and high
fibril density collagen materials maintained their inherent self-assembly, resulting in
preservation of native mechanical integrity and biological signaling properties of
collagen. Due to the ability of these implants in enhancing local neovascularization and
cellularization in an accelerated manner, these implants offer potential use as an ideal
platform for integrated tissue engineering and molecular therapy design.
For

improving the

vascularization ability of collagen scaffolds through VEGF

incorporation, a variety of approaches have been adopted in the past, including simple
physical entrapment, adsorption, and covalent immobilization as indicated in Table 6, and
through affinity based retention approaches shown in Table 7. However, simple physical
entrapment
collagen

(Table 6, approach A) or adsorption (Table 6, approach B) of VEGF in
can be

ineffective due to its rapid outward diffusion and quick loss of

bioactivity [192]. More serious problems such as abnormal, tortuous and leaky vessel
formation on account of the uncontrolled release of VEGF can lead to clinical failure of
constructs[296].

Therefore, to prevent uncontrolled release of VEGF, covalent

immobilization of VEGF has been developed (Table 6, approach C). While chemical
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immobilization was able to prevent passive diffusion of VEGF, it comes with a
disadvantage that chemical cross-linkers alter the inherent biological signaling capacity
of collagen and can result in adverse tissue responses [8, 77]. Moreover, it also presents
a danger of damaging the functional group or the screening of active pocket of the VEGF.
Table 6: Selective strategies used for VEGF delivery from collagen based delivery
systems
Strategy

Ref.
[335
337]
[317,
338342]
[343,
344]

Limitation
Noncollagenous
material
used
for
forming
micro-particle
in (A) causes
loss of physiological
relevance
Low
VEGF
loading
efficiency
Long period of
vascularization

Legend used in above schematics:
Chemical
crosslinker used
in strategy C
To surpass these limitations, heparin affinity based retention of VEGF in collagen
implants has emerged as an attractive option recently (Table 7). However, for heparin
incorporation, number of studies (Table 7, A-D) have used chemical crosslinker called
EDC

(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide)

hydroxysuccinimide)

and

NHS

(N-

that activates heparin for immobilization in collagen [64, 98, 307-

311]. While this cross-linking also serves to improve the mechanical strength and
proteolytic resistance of conventional collagen formulations, it alters the native
physiological structure of collagen due to chemical cross linkage [345].

As a result,

fibrillar mechanics is also affected, and since cell traction forces and adhesive behavior
depends on these fibril mechanics, any alteration to this native structure of collagen also
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affects cell proliferation and movement [330]. Furthermore, due to EDC/NHS chemical
crosslinking step, VEGF has to be loaded to the matrices in a last step, through
immersion or impregnation, resulting in low loading efficiency. Moreover, it is currently
not possible using EDC chemistry to independently vary implant stiffness vs. the amount
of immobilized VEGF [342]. Finally, the heparin quantities used for VEGF retention are
also high, and effect of heparin on collagen fibril mechanics is not always given,
although it is now known that heparin can alter both microstructure and mechanical
properties of collagen [327, 330, 332, 346-348].
We addressed these issues though a design strategy purely relying on affinity based
retention of heparin and VEGF as opposed to using exogenous chemical crosslinkers.
Exploiting heparin affinity for collagen and VEGF, we created heparin and VEGF
infused oligomeric collagen implants (Table 7, Strategy E) that retained their
physiologically relevant self-assembly properties as will be seen in following section.
3.4.1 Selecting heparin quantity that does not affect oligomer matrix self-assembly
In vivo, heparin based VEGF retention has been found to increase endothelial cell
proliferation, upregulate

microvasculature

formation,

and

stimulate

blood

vessel

maturation [64, 96, 349, 350]. However, in-vitro addition of heparin has illustrated that
these effects are concentration dependent and beneficial effects were found only at low
concentrations (0.1-1 μg/ml) of heparin [290, 351], while higher concentrations (10-1000
μg/ml) of heparin progressively inhibited the VEGF binding [291, 352]. These results
prompted us to carefully select heparin concentration for admixing to oligomer, so as to
obtain beneficial effects of VEGF binding.
Another important consideration in selecting heparin concentration for addition to
oligomer was its effect on collagen fibril self-assembly. Heparin is known to bind to type
I collagen fibrils with high affinity (Kd= 150 nM) [329]. However, several investigators
over the past few decades have reported that the presence of heparin during collagen
fibrillogenesis in vitro could have a profound concentration dependent effects on fibril
size, interconnectivity, diameter, and organization [327, 330, 332, 346-348], that could
impact cell growth [332]. Stamov et al. recently reported that these gross physiochemical
and morphology changes could be attributed to competitive binding of telopeptides and
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heparin to similar regions along the triple-helical main region of intact tropocollagen,
leading to inhibition of formation of asymmetric D-staggered fibrils [330].
Table 7: Selective strategies used for VEGF delivery from heparinized collagen
materials
Strategy

Ref.

Limitation

[353,
354]

Collagen
selfassembly
not
capitalized
;

[355,
356]

[98,
192,
308311]
[64,
357]

Chemical
crosslinking
used;
High
heparin
quantity;
Low
VEGF
loading
efficiency;
Slow
vasculariz
ation

This
work
Legends used in above schematics:
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Heparin bears the highest density of negatively charged groups among all other
GAGs [358] which can trigger the electrostatic interaction with other macroionic
molecules [359]. Heparin–type I collagen interactions likely rely on the basic triplehelical domain present at amino acid positions 87–94 near the N terminus of type I
collagen monomer, and at multiple sites within native fibrils [328, 329]. Weak heparin
binding sites were also observed near the carboxy terminal region of monomeric
tropocollagen between positions 755 and 933 [328, 360]. The regions containing
elements of NH2 terminus with affinity for heparin were highly basic, and found near the
interface between the overlap and gap region of collagen. However, these regions are also
known to be participating in the cross-link formations of collagen [328]. As telopeptides
and heparin are prone to bind to similar regions along the triple-helical main region, it has
been proposed that heparin binding at this position competitively inhibits the formation of
asymmetric D-staggered fibrils [330].
It was noted however, that the profound effects of heparin on the processes of fibril
formation, growth and higher-level organizations of collagen matrices were found to be
concentration dependent [327, 330, 332, 346-348]. While low concentrations of heparin
were reported to be promoting fibril formation, high concentrations inhibited fibril
assembly [327, 332, 333, 347]. However, the concentration range of heparin, ratio of
collagen and heparin, as well as the investigation techniques varied considerably in these
studies, making it difficult to paint a consistent picture of the important parameters of
heparin interaction with collagen. Moreover, these studies with heparin were carried out
on monomeric collagen formulations, not oligomer formulations. Therefore, before
employing the strategy of heparin based VEGF retention in oligomeric collagen, it was
extremely important to find the effect of heparin on oligomeric collagen polymerization
and viscoelastic properties.
We assessed this effect by adding heparin to 3 mg/ml oligomer solutions in concentration
range of 0 to 100 μg/ml through a simple admixing step, allowing electrostatic interaction
based binding of heparin to the oligomer molecule, and then assessed the effect of
heparin on matrix polymerization kinetics, viscoelastic properties and final stiffness of
polymerized oligomer matrices (Figure 19). Results of this study indicated that upto 1
μg/ml addition of heparin to oligomer collagen did not alter its mechanical stiffness,
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visco-elastic properties or polymerization kinetics. However, at higher concentrations (5,
10 and 100 μg/ml), the viscoelastic properties and stiffness of matrix decreased
significantly. These findings are consistent with previous findings where addition of
heparin in pepsin-solubilized bovine dermal collagen resulted in formation of a less
cohesive matrix [162, 327, 332].
While it is known that heparin and collagen form stable complexes due to electrostatic
interactions between the highly anionic heparin and the positively charged groups of
collagen [361, 362], the possibility that not all the added heparin binds to oligomer - was
taken into consideration. Some heparin could be merely physically entrapped in
polymerizing matrix. Since this free (unbound) heparin in collagen matrix could result in
its uncontrolled diffusion out of collagen, it was thought to eliminate any unbound
heparin from the collagen matrix using large excess of 1X PBS for 24 h. To quantify the
remaining heparin in washed matrices, we performed DMMB assay, exploiting the fact
that heparin forms colored complexes with the cationic dye 1, 9-dimethylmethylene blue.
All samples were papain digested before the assay to make entire amount of heparin
present in matrix accessible for the dye complexation [363].
The DMMB assay confirmed successful elimination of unbound heparin from oligomer
matrices, as the quantity of heparin in washed matrices was significantly lower than
unwashed matrices at all concentrations tested from 1 to 100 μg/ml (Figure 20 A). At 1
μg/ml heparin addition in oligomer, we found that approximately 26% of added heparin
was retained in the washed matrices. Further, confocal microscopy based visualization of
FITC-heparin in oligomer matrices confirmed heparin colocalization on oligomer
collagen fibrils and its retention after washing for 24 h (Figure 20 B and C). Such a
uniform spatial distribution of heparin in collagen and its intercalation in collagen fibrils
has been reported in previous studies [330, 348].
The results obtained here are important because they demonstrated for the first time the
effect of various concentrations of heparin on polymerization and visco-elastic properties
of oligomeric collagen. Based on these results, we selected 1 μg/ml concentration of
heparin for further design of VEGF retention system from oligomer, to preserve the
oligomer polymerization and viscoelastic properties while enabling VEGF retention.
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3.4.2 VEGF loading
Because of the reported strong affinity of VEGF 189 for ECM, and its beneficial role in
promoting vascularization in vivo, we incorporated VEGF 189 in our design strategy to
enhance vascularization potential of oligomer implants. VEGF dose was then carefully
chosen because of the evidences that over dosage of VEGF therapy can result in an
imbalance in angiogenic signals, leading to dysregulated vasculogenesis [364, 365] and
hemangioma-like assemblies [364, 366]. The amount of VEGF 189 used in this study
(0.5 μg/ml, or 0.125 μg

per implant) was chosen based on previous range of

concentrations of VEGF reported in similar assays that showed enhanced vascularization
effects in vivo either with heparin [64, 98, 307-311] or without heparin [205, 317, 339344]. For loading of VEGF to oligomeric matrix, we adopted admixing approach again,
where 0.5 μg/ml VEGF189 was added along with 1μg/ml heparin in the neutralized
oligomer solution and polymer self-assembly was induced at 37°C. Retaining both the
heparin and VEGF in collagen matrix was thus achieved through single step.
Since rapid, unregulated exposure of freely diffusible VEGF has been previously reported
to cause excessive but abnormal, unstable blood vessel growth [89, 367], we washed all
heparin and VEGF-containing oligomer implants for 24 h to remove any unbound
heparin and VEGF. The washing step resulted in loss of about 74% of heparin as
reflected by the results of DMMB assay for 1 μg/ml heparin-containing matrices.
Therefore, we suspected that the final quantity of VEGF remaining in the implants would
be very low. To quantify the exact amount retained in samples, we adopted LC-MS/MS
technique due to its higher sensitivity than ELISA method (Sensitivity of full MS was
500 fg buspirone on mass spectrometer column with signal to noise ratio of 100:1, while
sensitivity of standard Quantikine ELISA kit assay is 9 pg/ml). The samples were
enzymatically digested into peptides that were separated by high pressure liquid
chromatography (HPLC) and introduced into a mass spectrometer (Q Exactive™ HF
Hybrid Quadrupole-Orbitrap MS (Thermo Scientific, Waltham, MA) for fragmentation
and sequencing to identify the parent proteins. However, the large presence of collagen in
the samples obscured the VEGF detection in samples (data not shown).

To determine

whether the VEGF remaining in oligomer implants was able to promote higher
vascularization in vivo, it was therefore thought to assess the effect of oligomer alone
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(without heparin or VEGF) on CAM, followed by its comparison with the VEGF and
heparin-infused implants. The results of this study are discussed in the following section.
3.4.3 Evaluation of oligomer implant's vascularization potential in CAM assay
To evaluate the vascularization potential of oligomer matrices in CAM, we implanted
oligomer constructs on CAM at embryonic day 9, and after 3 days of incubation, we
scored the CAM vessel density and distribution around the implants. The vascular
response was also evaluated for occurrence of any tortuous, irregular, or fine, brush like
vessels, as it could be an indication of abnormal and leaky vessel formation [89, 368].
Furthermore, to evaluate the vascular ingrowth from CAM into the implants, we
performed histology and H&E staining on transversally cut implant samples that allowed
us to envision both capillary formation and cellularization in the internal sections of the
implants.
3.4.3.1 Validating functionality of oligomer implants on CAM
The first goal was to validate the suitability of oligomer constructs for implantation in
CAM, and evaluating their vascularization potential in CAM, as compared to the
commercial Integra collagen samples, and paper disc samples. Integra collagen used in
this study was an absorbable wound dressing sponge made of collagen obtained from
bovine deep flexor (Achilles) tendon, and it was chosen for comparison in this study
since it is FDA approved and has been used successfully in clinical trials for treating
wounds [369, 370].
Results of 3 day implantation on CAM demonstrated that 3 mg/ml oligomer induced
higher vascular response on CAM compared to the Integra collagen implants or paper
disc samples (Figure 22). Histology results further provided evidence that oligomer
implants supported cell invasion from CAM into the collagen region in just 3 days after
implantation. Cell infiltration was also found in Integra samples. However, large empty
spaces were characteristic of Integra collagen, as opposed to uniform, dense fibrillar
nature of oligomer sample. CAM cells invading the paper disc sample showed apoptic
morphology, which can be attributed to the absence of collagen matrix that provides
essential mechanical support and biological signaling for

cellular

growth and
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proliferation. The higher induction of vascular response on CAM while maintaining cell
infiltration as shown by oligomer implants, established them as suitable material for
further vascularization study.
3.4.3.2 Low fibril density heparinized oligomer implants promoted enhanced
vascularization in CAM
Having established suitability of oligomer implants in inducing vascularization on CAM,
we next evaluated whether heparin and VEGF addition to oligomer implants enhanced its
vascularization ability. Results indicated that heparinized oligomer implants containing
VEGF induced highest vascular response on CAM among all groups (Figure 23). This
enhancing effect of heparin and VEGF has been observed previously, both in vitro [309,
355] as well as in vivo [98, 310] although the time required for vascular effect was
reported to be higher than 3 days. Moreover, these studies incorporated heparin in
collagen matrices through EDC/NHS chemical cross-linking for VEGF retention. Here
we obtained improved vascularization results through simple admixing of heparin and
VEGF in oligomer, in an accelerated period of 3 days.
The non-heparinized oligomer implants containing free VEGF also demonstrated
angiogenic activity on CAM, however, the vessels formed around this group of implants
were either brush like, or tortuous, indicating an abnormal vessel development. Such
abnormal vessel development could be a result of passive, uncontrolled release of VEGF
out of the oligomer implants. Similar to these findings, previous reports have indicated
formation of chaotic capillary plexus in vivo in response to freely diffusible VEGF
released from fibrin matrices, while matrix-bound VEGF induced formation of highly
organized, functional vessels in CAM [89, 371].
It addition to VEGF loaded implants,

heparinized oligomer implants without VEGF

(Coll+Hep) also induced a vascular response on CAM, although it was weaker than
Coll+Hep+VEGF group. The positive angiogenic effect of heparin by itself on CAM
vasculature has been reported previously [372-374]. In the absence of exogenous growth
factors, modification of collagen with heparin was found to increase neovascularization,
possibly by potentiating endogenous growth factors present in vivo [59, 64, 98]. This
positive effect of heparin could have been due to its role in protecting cell secreted
VEGF from degradation [192], and upregulating VEGF activities by enabling its binding
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to the

KDR and Flt-1 receptors [375]. Finally, the non-heparinized oligomer implant

(Coll), showed a vascular response that was significantly lower than either VEGF or
heparin or both VEGF and heparin loaded matrices. Together, these results highlight the
potential of heparin in retaining VEGF in oligomer implants and upregulating its
activities on CAM. These results also convey the importance of controlled VEGF release
essential for formation of normal vasculature on CAM, which was achieved in our system
using simple affinity based retention of VEGF.
3.4.3.3 Enhancing CAM vascularization through high fibril density implants
The vascularization potential of low-fibril density oligomer implants can be beneficial in
cases such as small injuries or as acute wounds, where the low mechanical properties of
the implants could suffice tissue healing for a short period of time. However, in cases
such as chronic wounds, where the regeneration of new tissue is difficult due to high
level of proteases [189, 376], the implants would be required to last longer to support and
accelerate new capillary ingrowth into the implant. For this purpose, oligomer implants of
high fibril density can offer a potential solution due to their characteristic

higher

mechanical strength and resistance to proteolytic degradation [116]. Moreover, the
increased fibril-density would have a positive effect on retaining the encapsulated growth
factors [4], due to their enhanced fibril density (reduction in pore size) [183]. Therefore,
with an objective to provide stronger mechanical support and enhanced VEGF retention,
we prepared high fibril-density 20 mg/ml oligomer implants loaded with heparin and
VEGF and evaluated their ability to accelerate local vascularization in CAM after 3 days
of implantation.
Results of 20 mg/ml implants (Figure 24) were similar to 3 mg/ml implants, where
heparinization and VEGF incorporation of the implants led to significantly higher
vascularization.

VEGF-containing implants

without heparin led to brush-like or

tortuous/abnormal vessel response again, emphasizing that uncontrolled VEGF release
had undesirable consequences on normal vasculature development of CAM. Heparinized
implants without VEGF showed a weaker vascular response than with VEGF loading.
Oligomer implants without heparin or VEGF incorporation showed significantly lower
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vascular response. These results corroborated the advantages of incorporating heparin
and VEGF together in oligomer scaffolds, to achieve enhanced neovascularization.
Apart from maintaining their ability to promote vascularization, another remarkable
result demonstrated by the 20 mg/ml implants was their ability to retain their shape and
exposing large area for growth of CAM vasculature even on day 3 of implantation. In
fact, the 20 mg/ml implants retained largest cross-sectional area among all the collagen
implants tested in this study (Table 5), which can be a result of the high mechanical
integrity of these constructs. Most collagen implants without the aid of exogenous
crosslinking suffer from the drawback of low mechanical integrity, rapid degradation and
fast diffusion of growth factors [4, 5]. Therefore, considering the lack of exogenous
crosslinking in our study, the results obtained here in terms of preservation of mechanical
integrity, retention of VEGF and promotion of vascularization on CAM were found to be
impressive.
3.4.4 Cellularization of oligomer implants
The induction of high vascular response around both 3 and 20 mg/ml oligomer implants
containing heparin and VEGF informed us about the effect of heparin and VEGF delivery
from oligomer on CAM vasculature. However, for clinical success of tissue-engineered
scaffolds, along with promotion of vascularization around the implant, growth of micro
vessels within the implant is crucial to enable survival of cells in the core of the scaffold
[296]. CAM assay allows the advantage of envisioning such a microvasculature growth
inside scaffolds that can be separated from the surrounding CAM vasculature, as these
new micro vessels grow inside the scaffolds against gravity [326, 377, 378]. We
evaluated the ability of oligomer implants to draw in such micro vessels, through H&E
based staining of transverse histological sections of the implants (Figure 26).
Results revealed that non-heparinized implants supported cellular infiltration, however,
these cells were not aligned towards any particular direction.

VEGF loaded non-

heparinized induced formation of several capillaries on CAM adjacent to the implant
periphery, but not within the implant. In contrast, heparinized oligomer implants loaded
with VEGF induced formation of several capillaries inside the implants, clearly showing
the benefit of adding heparin in upregulating vasculature inside the oligomer implants. As
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proposed in previous studies [64, 97, 349, 379], this upregulation of neovasculature
inside collagen implants could have on account of the prolongation in VEGF's biological
activity [202, 380] and more efficient binding of VEGF to its receptors in presence of
heparin [355, 380].
Another outstanding result of implanting heparinized VEGF-containing oligomer on
CAM was highest invasion of CAM cells within the implants. These cells also displayed
remarkable alignment towards the implant, which could be a result of VEGF signaling
gradient present across the boundary of oligomer implant and CAM. Physiologically,
such a VEGF gradient in hypoxic or diseased tissues [381], exercising skeletal muscle
[381, 382], and wounds [383] has been shown to be responsible for attracting endothelial
sprouts towards hypoxic regions. A putative gradient of VEGF formed in collagen
implants has also been reported previously to be responsible for cell recruitment in other
studies involving VEGF [341] and other growth factor delivery through collagen
implants [384]. Therefore, the increased infiltration of CAM cells within heparinized,
VEGF-containing oligomer implants obtained here could have been a consequence of
presence of such a concentration gradient created across the interface of oligomer
implants and CAM.
In the present study, the process of vascularization of heparinized oligomer matrices was
seen to be accompanied by a remodeling of the matrix (Figure 26 D and H), and this
process is also known to occur in physiological healing of wounds [385]. The
physiological remodeling of wound includes degradation of the collagen through matrix
metalloproteinases (MMPs) [386] secreted by infiltrating fibroblasts that then deposit
newly synthesized collagen [192, 387]. In our CAM study, the cells infiltrating in
oligomer matrix could be participating in such activities, subsequently remodeling the
collagen matrix they resided in, generating their own micro-environment and,
proliferating, differentiating and attracting other cells inside the collagen [384].
While

several studies

reported

that

modified

collagen implants

increased in

neovascularization on the CAM surface [64], very few [334] have documented actual
neovascularization inside the collagen matrix
reported that neovessels

of the implant. Kilarski et al. [334]

found in their collagen matrix were contained within the

expanding CAM tissue that eventually replaced the provisional matrix and there was a
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clear demarcation between the ingrowing tissue and the implanted gel, implying that the
neovessels entered their collagen gel as a part of ingrowing CAM tissue buds, but not as
independent entities. In our model however, we found capillaries both inside the
ingrowing CAM tissue as well as inside collagen as separate entities, in addition to the
capillaries on CAM tissue on periphery of the implant. Furthermore, such cellularization
and neovascularization was obtained in just 3 days, while several collagen implant
studies have required several days for cellularization of their constructs in either CAM or
rat subcutaneous implantation studies [64, 98, 307-311]. In the light of the current stateof-the-art collagen induced vasculature on CAM, oligomer constructs that demonstrated
this distinct microvasculature as well as cellularization inside them appears very
promising for promoting tissue regeneration and integration with the host tissue.

3.5

Conclusion

Physiologically, the process of vessel formation takes place in the ECM, that
constitutes

a dynamic 3D microenvironment of cells, providing the instructive

biomechanical and biomolecular signaling required for morphogenesis. The ECM is the
natural biological material, which with the help of molecules such as heparin sulphate
proteoglycans or heparin, regulates the sprouting of new blood vessels, and their
stabilization, leading to restoration of functional blood circulation into ischemic tissues.
Inspired by this role of ECM and heparin in spatio-temporal regulation of growth
factors in vivo, we designed a physiologically relevant collagen implant from selfassembling oligomer molecules that can control the local presentation and release of
VEGF at the site of implantation. We leveraged heparin's affinity for oligomeric
collagen molecules and VEGF189 for this purpose, enabling a single step local
retention of VEGF189 in the oligomer implants for promotion of vascularization.
We then validated the functionality of the oligomer implants in promoting vascularization
and cell infiltration in vivo, through the use of simple and reproducible CAM assay.
When compared and contrasted with paper discs, Integra collagen, and non-heparinized
as well as free VEGF loaded implants, we found a clear benefit of heparin addition in
oligomer implants that resulted in formation of robust neovascularization in an
accelerated time period of 3 days. We also demonstrated that the vasculature response
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can be controlled by altering contents (heparin and VEGF loading) as well as the fibril
density of oligomer implants. VEGF loaded implants without heparin led to formation of
tortuous vessels, corroborating the dangers of uncontrolled VEGF therapy. In contrast,
heparinized implants loaded with VEGF demonstrated improved and stable vasculature
formation both around and within the implants, signifying the importance of heparin for
controlling the VEGF release.
While CAM assay allowed us to evaluate the viability of oligomer implants as angiogenic
biomaterial, in a rapid, simple, and low-cost in-vivo setting, it should be noted that this
model system is an intermediate step between a cell culture and a large animal studies or
more complex mammalian model. Therefore, the positive results of enhanced
vascularization through heparinization of oligomer implants obtained in this study must
be tested in a large animal and mammalian model, and the differences between avian and
mammalian biology should be taken into account before applying any conclusions from
CAM assay to a mammalian model [388].
Finally, it is worth mentioning that the implants designed in this work were fabricated
without the use of exogenous crosslinkers, and the heparin quantity chosen for loading
VEGF did not affect oligomer collagen self-assembly. Consequently, the designed
implants retain collagen’s multi-scale structural features and inherent biological signaling
capacity while promoting microvasculature formation inside the implants in an
accelerated manner. Accelerated vascularization in turn can shorten the time of
cellularization of constructs, decrease the risk of infection, and result in faster tissue
integration and regeneration or healing of the affected tissue [389], thus providing an
ideal platform for integrated tissue engineering and molecular therapy design.
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CHAPTER 4.

4.1

CONCLUSION & FUTURE WORK

Conclusions

There is a significant challenge in the design and manufacture of multifunctional biograft
materials capable of providing tunable molecular delivery due to the poor mechanical
properties, rapid proteolytic degradation, and inability of collagen formulations to
demonstrate physiologically relevant self-assembly. This work attempts to address these
limitations with the use of novel self-assembling collagen-fibril biograft materials.
Overall, we achieved a successful design and development of self-assembling,
multifunctional 3D collagen-fibril biograft materials with a broad range of tunable
physical and molecular delivery properties. More specifically, collagen polymers
specified by their intermolecular crosslink composition and self-assembly capacity were
used to customize and design materials in terms of 1) collagen fibril microstructure and
2) proteolytic degradability. Furthermore, to increase local retention of biomolecules such
as vascular endothelial growth factor (VEGF) in collagen, we successfully employed
affinity based strategy that exploited the VEGF-binding and collagen-binding capacity of
heparin. The functionality of collagen biograft materials was demonstrated in an in-vivo
CAM model, where

enhanced local retention of VEGF led to increase in

neovascularization and cell infiltration of collagen biografts.
Specifically in Chapter 2, we found that when compared with the conventional collagen
monomer (e.g., atelocollagen, telocollagen) matrices, oligomer matrices exhibited
uniform, highly branched fibril ultrastructure and possessed higher resistance to
proteolytic degradation. As a result, oligomer matrices exhibited size-dependent and
sustained molecular release while conventional telocollagen matrices showed burst
release for small as well as large sizes of FITC-dextrans.

Fibril microstructure and

proteolytic degradability was also significantly affected by varying the collagen polymer
building blocks (e.g. oligomer, telocollagen and atelocollagen) used for self-assembly.
Most contrasting release profiles were obtained using oligomer and atelocollagen
building blocks, with oligomer showing most sustained release while atelocollagen
showing most rapid release in both absence and presence of collagenase. Molecular
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release of both small and large molecules was further fine-tuned by combining oligomer
and atelocollagen in different percentages. Increase in oligomer percentage extended the
molecular release time observed through mixed matrices. An enhancement in molecular
retention was further achieved by increasing collagen fibril density that also improved
resistance of materials against collagenase. Collectively, through these results, we
demonstrated successful development of collagen fibril biografts that could be tuned in
terms of their fibril microstructure and proteolytic degradability for providing tunable
molecular release of wide range of molecular sizes.
In Chapter 3, we validated the functionality of these collagen biografts for promoting
local vascularization and cell infiltration using an established in-vivo CAM assay through
controlled VEGF delivery. Here, to increase local retention of VEGF in collagen, we
employed affinity based strategy that exploited the VEGF-binding and collagen-binding
capacity of heparin. Results showed a clear benefit of adding heparin to oligomer
matrices, leading to an increased vascular response on CAM and enhanced
neovascularization as well as cell infiltration of the implants. We further demonstrated
that response was dependent on the absence or presence of heparin and VEGF in
oligomer implants and the fibril density of oligomer implants. VEGF loaded implants
without heparin led to formation of tortuous vessels, corroborating the potential dangers
observed with uncontrolled VEGF therapy by researchers in the past. In contrast,
heparinized implants demonstrated stable vasculature response both around and within
the implants, signifying the importance of heparin for controlling the VEGF release.
Overall, the heparinization prevented uncontrolled VEGF release from collagen and led
to a remarkable increase in neovascularization and cellularization of the implants in a
short period of 3 days.
Altogether, this work indicates that the collagen polymers specified by their
intermolecular crosslink composition and self-assembly capacity can be used effectively
to fashion a broad range of multifunctional collagen-fibril biograft materials with tunable
physical and molecular delivery properties in absence of excessive processing and
exogenous crosslinking. These highly porous collagen materials comprise D-banded
fibrils, resembling those found in tissues, and maintain their inherent biological signaling
properties. The remarkable ability of these designer implants in supporting enhanced
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neovascularization and cellularization of the constructs in an accelerated period indicates
their strong potential as an ideal platform for integrated tissue engineering, regeneration
and molecular therapy design.

4.2

Future Work

Since the motivation to develop collagen based tissue engineering implants is to address
unmet clinical need of soft tissue replacement, the ultimate success in its clinical
translation will depend on an interactive, back and forth, “bedside to bench and back
again” approach that has recently emerged [390]. For the designer collagen biografts
studied in this work to reach patient care in the near future, such an approach is of utmost
importance. Many indispensable steps should be met with in this approach, the first and
foremost being in-vivo trials using small and large animal models to evaluate safety and
efficacy of the biografts for desired clinical need.
A specific example of such a clinical need where the collagen biografts developed in this
work could be applied, is the treatment of chronic wounds such as diabetic ulcers. As
mentioned in first chapter of thesis, diabetic ulcers result in significant morbidity,
prolonged hospitalizations, and enormous healthcare costs. Therefore, the efficacy and
safety of collagen biografts to heal diabetic ulcers could be shown using non-healing
wounds in a diabetes-induced animal model [391]. Among the various animals that can
be used for this purpose, such as rabbits, dogs, goats, sheep, or pigs, we propose the pig
model studies, because of their known anatomical and physiological similarities to
humans[392]. Diabetes can be induced in pigs via streptozotocin injection[391]. Full
thickness wounds can then be introduced in pigs to create diabetic ulcers. Collagen
biografts will then be implanted on the wounds and untreated wounds will serve as
controls.
The pig experiment will be carefully designed to include all variables in the biograft and
each variable will be tested separately. As required by law, the animal research protocol
would then be submitted to the Institutional Animal Care and Use Committee (IACUC)
for approval.

The outcome of the pig model study would be immensely valuable in

determining the safety and efficacy of the collagen biografts, and would pave the way
forward for future clinical translation to address unmet need of treating chronic wounds.
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APPENDIX A. TYPE I COLLAGEN BASED DRUG DELIVERY
FORMATS

Table A: Examples of Type I Collagen-based Drug Delivery in Research

1. Gels
Molecules
delivered
Pilocarpine [393]

In vitro/vivo Applications

Drug binding approach

Ophthalmic treatment

TGF-β3 [394]

Craniocynostosis treatment

Doxorubicin [395]

Cancer chemotherapy

Keterolac [396]
Transforming
growth factor TGFβ2 [100]
growth
factor
R136K-CBD [397]

Treating inflammation
Facilitating tissue repair

Smooth
Muscle
Proliferation

Physical: Direct Admixing in
collagen solution, then allowing
collagen to polymerize into gel
by incubation in 37°C.

Chemical: Covalent binding to
collagen through difunctional
PEG
Cell Chemical: Chimeric collagen
binding
domain
based
attachment

2. Shields
Plasmid DNA [129]

Gene therapy for healing after Physical: Plasmid absorbed into
glaucoma surgery
the collagen shield
Gentamicin GA and Antibiotic therapy through
Vancomycin
VA collagen contact lenses
Physical: Presoaking collagen
[398]
shield in drug solution right
Keratoplasty treatment
before application
Tobramycin,
Pilocarpine [399]
3. Membrane/Sheet
Vascular
Useful for paracrine assays Physical: Admixing in collagen
Endothelial Growth and angiogenesis
gel followed by vitrification
Factor VEGF [400]
Transdermal delivery devices Physical: Mixing in alginate and
Nifedipine [401]
for wound dressings
then into collagen membrane
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Table A (continued)

4. Microspheres/nanoparticles
Retinol,
tretinoin, Carriers for lipophilic drugs
or tetracaine and
lidocaine in free
base form [402]
Cyclosporines
Delivery to the ocular surface
[403]
to prevent corneal graft
rejection
5. Sponge
Retinoic acid RA Endothelial regeneration in
[404]
prosthetic bypass grafts
5-Fluorouracil
[405]

Physical:
Collagen-particles
encapsulating
cyclosporine
suspended in methyl cellulose
Chemical: Chimeric
binding to sponge

domain

Reduces intraocular pressure
wound healing

Gentamicin
[142]

Physical: Drug encapsulated by
emulsion into
cross-linked
collagen microspheres

[143]

Physical: Lyophilized sponge
rehydrated and soaked in
drug/growth factor solution

Bone remodeling

rhBMP-2 [145]
It can be seen from above table that the versatility of collagen lends itself well to a
variety of medical applications including but not limited to wound care, oral surgery,
cardiovascular systems, neurology, urology, and orthopedics. The formats of collagen
used in these applications are many, and selective examples are described below.
Sponges: Collagen sponges were originally developed as wound dressings due to
their ability to absorb large quantities of tissue exudates, adherence to wet wound bed
with preservation of low moist environment and shielding against mechanical harm and
secondary bacterial infection [406]. Growth factors have been coated on collagen sponge
to give recovery from dermal and epidermal wounds [138, 139]. Collagen sponges are
generally prepared by lyophilizing aqueous collagen preparations [4] which yields
collagen sponges with high porosity and fibril interconnectivity. The porosity of the
lyophilized collagen can be altered by varying the collagen concentration and the freezing
rate, which allows for some degree of control over the design of the sponge [407].
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Another method of loading lyophilized sponge, apart from coating them with drug
solution, is to soak the sponge in aqueous drug formulations prior to implantation. For
example, porous collagen sponges have been soaked in antibiotic solutions (e.g.,
gentamicin) [142, 143] and in growth factor solutions (e.g. rhBMP) for delivery to tissue
of interest [145]. In addition, collagen can be combined with other materials like such as
elastin [408], fibronectin and hyaluronate [409] or glycoaminoglycans [410, 411] to aid
in the delivery of drugs which do not interact well with collagen. The starting collagen
material can be cross-linked with agents like glutaraldehyde and dehydrothermal
treatments (DHT) in order to achieve highly resilient materials [410, 411]. However, the
use of such cross-linking agents is not always effective as discussed in section 6. Sponges
also suffer from the problem of releasing the entrapped factors quickly [159], giving a
burst release profile in most cases [4].
Gels: Collagen gels are primarily used in aqueous injectable systems that are
initially liquid but solidify after administration to the tissue. In situ polymerization
methods offer an advantage of injectability and spatial control with better mechanical
properties over other collagen-based devices such as implantable collagen sponges or
sheets. For most gel formulations, the drug is admixed or physically entrapped with
collagen in liquid form at a certain ratio, and then allowed to gel when the temperature is
raised to 37 °C (body temperature), as is the case with drugs such as pilocarpine, TGF-β,
doxorubicine and ketorolac (Table 2) [393-396]. Although such collagen gel systems
show promise in drug delivery, their open pore structure cause diffusion-dominated
release, which is undesirable due to little or no control over drug release rates.
Shields: Collagen shields have been primarily used as therapeutic devices for
ophthalmological conditions such as plasmid delivery for glaucoma treatment or contact
lenses to promote corneal epithelial healing and deliver hydro soluble drugs [129].
Shields typically start in a dehydrated form and have to be soaked with drugs in liquid
solution prior to application. The thin collagen films conform to the shape of the cornea
when applied to the eye and are able to provide sufficient oxygen transmission, as well as
act as short term bandage lenses [412]. As the shields dissolve, they provide a layer of
collagen solution that lubricates the surface of the eye, minimizes rubbing of the lids on
the cornea, and fosters epithelial healing [65]. However, some disadvantages still limit
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the application of collagen shields such as incomplete transparency, slight discomfort,
complex insertion technique, and short period of working before dissolution. For
mechanical strength imparting reason, cross-linking is performed on shields already
loaded with drugs, but that endangers the chemical integrity of the active substance [160].
Microspheres:

Collagen

microparticulate

systems

have

been

used

for

encapsulating number of antibiotics, steroids, growth factors, and hydrophilic and
hydrophobic drugs for therapeutic purposes due to their small particle size, large surface
area, and ability to disperse in water to form colloidal solutions [65]. Microspheres can
provide regulation of release by controlling the shell material and protection of drug until
its delivery is needed [413].

Moreover, microspheres can create gradients in the

concentration of growth factors that can direct cell migration, create patterns of cell
differentiation an direct tissue organization into complex structures such as branching
networks of vascular systems [107].
Despite many successful studies on collagen microspheres, the transition to
collagen as the primary biomaterial for microsphere technology is hindered by limitations
in manufacturing material, methods, and use of solvents due to risks of collagen
denaturation. Most of the methods of formulation are tedious, requiring that each step
(i.e. droplet generation, gelation, and extraction) be performed separately [414].
Furthermore, microsphere prepared have to be cross-linked exogenously in most cases, in
order to avoid the possibility of losing the mechanical integrity and shape of device, but
that leads to detrimental effects of exogenous cross-links.
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APPENDIX B. STATE-OF-THE-ART METHODS OF TUNING
COLLAGEN BASED MOLECULAR RELEASE

Table B: Strategies of tuning molecular release from collagen based materials and
their limitations
Strategy

Example

Molecule
delivered

Release Ref.
period

Varying
extent of
exogenous
crosslinking

Crosslinking with
Glutaraldehyde

Vascular
Endothelial
Growth Factor
(VEGF)

30 days

[317]

Crosslinking with
four-arm poly
(ethylene glycol)
terminated
succinimidyl
glutarate (4SStarPEG)

siRNA

10 days

[415]

Crosslinking with
N-(3dimethylaminoprop
yl)-N′ethylcarbodiimide
(EDC) and Nhydroxysuccinimid
e (NHS).

heparin

Crosslinking with
metal oxide
nanoparticles (NPs)
and PVP capped
ZnO (ZnO/PVP) in
addition to UV
crosslinking

pilocarpine
hydrochloride
(PHCl)

11 days

[379]

Limitation
Detrimental effects
on cells and tissues,
such as cytotoxicity
or tissue calcification;

Release
requires
hydrolysis
of
a
linking bond which is
different from in-vivo
proteolytic
degradation;

Crosslinking
with
additives
increases
complexity of system

14 days

[131]

Crosslinking reagents
can also react with
and
affect
noncollagen
structural
proteins,
glycosaminoglycans,
growth factors and
other
bioactive
compounds, or cells
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Table B (continued)

Chemical
modification
of collagen
to enable
ionic
bonding
between
drug and
collagen

Succinylating
collagen sponge
and film with drug
dispersed in poly
(N-vinyl-2pyrrolidione) (PVP)
solution

Ciprofloxacin (a 5 days
cationic
fluoroquinilone
antibiotic).

[141]

Succinylated
collagen gels do not
appear to have a long
lifetime in vivo,
usually disappearing
within 24 h
depending on the
degree of
succinylation

Covalent
immobilizati
on of drug

Crosslinking with
di-functional or
multi-functional
succinimidyl ester
polyethylene glycol
(PEG, 3.4 to 10
kDa)

transforming
growth factor
beta-2 (TGFbeta2)

5 days

[100]

Crosslinking with
SS-PEG-SS

VEGF

72 hrs

[416]

Covalent conjugation
can be difficult to
control, produce poor
reaction yields, and
even compromise the
biochemical features
of the protein/drug or
collagen itself

Poly(dialdehyde)
guar gum
(PDAGG) based
covalent
crosslinking of
biomolecules with
collagen

platelet derived
growth
factor (PDGF)

13 days

[417]

Heparin

basic fibroblast
growth factor
(bFGF)

10 days

[94]

Fibronectin

Recombinant
human bone
morphogenic
factor 2
(rhBMP-2)

7 days

[418]

Adding
intermediate
proteins
with affinity
for collagen
and protein
of interest

Binding interactions
are specific to each
drug and hard to
predict;
Very little tuning if
the binding
interaction is weak
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Table B (continued)
Mixing
collagen
with
other
synthetic
or natural
polymers

Hybrid scaffolds of collagen
and poly (lactic-co-glycolic
acid) microbeads were
prepared by introducing
insulin-releasing poly (lacticco-glycolic acid) microbeads
into collagen porous scaffolds.
Pore structure was controlled
using ice particulates.

Insulin

4 weeks

[419]

Collagen–
hydroxyapatite scaffolds
combined with either alginate
or poly(lactic-co-glycolic acid)
(PLGA) microparticles

rhBMP-2

28 days

[420]

Addition of BMP-2 into soft
PEG hydrogels before infusion
in to the solid collagen/HA
sponges

BMP-2

40%
release
observed
in 15
days

[421]

collagen and poly(caprolactone)

gentamicin
and
amikacin

60 hrs

[422]

collagen impregnated with
drug loaded alginate
microspheres

antibacteria
l agent
silver
sulfadiazin
e (AgSD)

66.8%
released
in 72 hrs

[423]

lyophilizing solution of
suspended PLGA
microparticles in a collagen
dispersion

gentamicin

7 days

[424]

Drug containing liposome
sequestration in collagen gel

Insulin
Growth
hormone

5 day

[425]

14 day

Reduction
in
material's
cellinstructive
capacity
and its
inability
to
integrate
with host
tissue,
can make
the
clinical
translation
of
products
very
difficult
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Table B (continued)
Engineering
peptides with
collagen
binding
domain
(CBD)

Fusion protein consisting
of hepatocyte growth factor
(HGF; an angiogenic
factor) and a collagenbinding domain (CBD)
polypeptide of fibronectin
was produced in a
baculovirus expression
system

Hepatocyte
growth
factor
(HGF)

[426433]

1 week

Addition of
collagen
mimetic
peptides
(CMPs)

CMP-modified polyplexes
are bound to
collagen via thermally
induced annealing that
induces CMP strand
invasion and CMPcollagen triple helical
hybridization

Gene

1 month

[257]

Native
collagen
microstruc
ture is
modified

Vitrification
of collagen
membrane

Collagen gel was dried for
2 weeks to convert into a
rigid glass-like material,
which was rehydrated with
PBS containing VEGF

VEGF

14 days

[400]

Native
collagen
microstruc
ture is
modified

After gelation, collagen
membranes were formed
by vitrification for 2 days,
followed by rehydration
with PBS containing BMP2

BMP-2

>80%
[434]
retained
even after
15 days

[426]

Complexit
y of such
systems is
a
disadvanta
ge from a
commerci
al
perspectiv
e
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Table B (continued)
Increasing
collagen
density

Collagen content varied
from 1.5% to 2.0% and 2.5
%, pexiganan release from
collagen was found to be
extended from 24 h to 48 h
and 72 h respectively

FITC
coupled
Pexiganan
(a 22
amino acid
antimicrobi
al peptide)

72 h

[262]

A membrane consisting of
photo polymerized
polyethylene glycol
dimethacrylate (PEGDM)
and interconnected
collagen microparticles
(COLs) was used and
collagen concentration
varied from 100 mg/ml to
300 and 500 mg/ml

40-kDa
FITCdextran,
and

42 days

[204]

Concentration of type I
collagen hydrogels was
varied from 1.5 to 4.5
mg/ml; drug interaction
also played a role in tuning
the release

pBMP-9

72 h

[263]

recombinan
t human
brainderived
neurotrophi
c factor
(rhBDNF)

Can limit
cell
migration/
infiltration
into the
densified
collagen
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